WO2024121385A1 - Régime à deux doses en immunothérapie - Google Patents

Régime à deux doses en immunothérapie Download PDF

Info

Publication number
WO2024121385A1
WO2024121385A1 PCT/EP2023/084892 EP2023084892W WO2024121385A1 WO 2024121385 A1 WO2024121385 A1 WO 2024121385A1 EP 2023084892 W EP2023084892 W EP 2023084892W WO 2024121385 A1 WO2024121385 A1 WO 2024121385A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
car
dose
day
seq
Prior art date
Application number
PCT/EP2023/084892
Other languages
English (en)
Inventor
Mark Gerard FRATTINI
Kathryn Jean NEWHALL
Ana Beatriz Corrêa KORNGOLD
Original Assignee
Cellectis S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis S.A. filed Critical Cellectis S.A.
Publication of WO2024121385A1 publication Critical patent/WO2024121385A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/25—Suicide switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Definitions

  • the present document generally relates to the field of cancer, in particular, cell therapies and immunotherapies for the treatment of solid tumors or haematological cancers in patients.
  • Adoptive cell therapy also known as cellular immunotherapy, is a form of treatment that uses the cells of the immune system to eliminate pathological cells, such as infected or malignant cells.
  • Some of these approaches involve directly isolating a person’s own immune cells and simply expanding their numbers, whereas others involve genetically engineering immune cells from patients (autologous approach) or donors (allogeneic approach) to boost and/or redirect them towards specific target tissues.
  • immune cells especially immune cytolytic and helper T-lymphocytes, Natural Killers and Macrophages, are particularly powerful against cancer, due to their ability to bind to markers known as antigens on the surface of cancer cells.
  • TIL Tumor-Infiltrating Lymphocyte
  • TCR Engineered T Cell Receptor
  • CAR Chimeric Antigen Receptor
  • NK Natural Killer
  • Chimeric antigen receptors-expressing immune cells are cells that have been genetically engineered to express chimeric antigen receptors (CARs) usually designed to recognize specific tumor antigens and kill cancer cells that express said tumor antigen(s). These are generally T-cells expressing CARs (“CAR-T cells”), Natural Killer cells expressing CARs (“CAR-NK cells”), or macrophages expressing CARs.
  • CAR-T cells T-cells expressing CARs
  • CAR-NK cells Natural Killer cells expressing CARs
  • macrophages expressing CARs are cells that have been genetically engineered to express chimeric antigen receptors (CARs) usually designed to recognize specific tumor antigens and kill cancer cells that express said tumor antigen(s). These are generally T-cells expressing CARs (“CAR-T cells”), Natural Killer cells expressing CARs (“CAR-NK cells”), or macrophages expressing CARs.
  • CAR-T cells T-cells expressing CAR
  • CARs are synthetic receptors consisting of a targeting moiety that is associated with one or more signalling domains in a single or multiple fusion molecule(s).
  • the binding moiety of a CAR can include an antigen-binding domain of a single-chain antibody (“scFv”), comprising the light and heavy variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully.
  • the signalling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta (or CD3Q or the Fc receptor gamma chains.
  • First generation CARs have been shown to successfully redirect T-cell cytotoxicity, however, they failed to provide prolonged expansion and anti-tumor activity in vivo.
  • Signalling domains from co-stimulatory molecules including CD28, OX-40 (CD134), ICOS, and 4-1BB (CD137) have been added alone (second generation) or in combination (third generation) to enhance survival and increase proliferation of CAR modified T-cells.
  • CARs have successfully allowed T-cells to be redirected against antigens expressed at the surface of tumor cells from various malignancies including lymphomas and solid tumors (Jena, Doth et al. Blood (2010) 116(7):1035-44).
  • Adoptive immunotherapy which involves the transfer of autologous or allogeneic antigen-specific T-cells generated ex vivo, is a promising strategy to treat viral infections and cancer as confirmed by the increase in the number of clinical trials involving CAR-T cells.
  • CAR-Ts have been administered according to a single dose strategy, possibly repeated if the first dose was not sufficient to lead to a complete patient’s response, or according to a split dosing strategy to reduce toxic effects.
  • This document provides methods and materials for treating cancer. For example, this document provides a new regimen of administration of CAR-T cells that improves the efficacy of the treatment. It is to be understood that both the foregoing general description of the embodiments and the following detailed description are exemplary, and thus do not restrict the scope of the embodiments.
  • the methods and materials provided herein are particularly suited for treatment of cancers characterized by the presence of CD 123 in the tumor.
  • the methods and materials provided herein also are particularly suited to achieve a “universal” treatment, where the components of the treatment can be used in many unrelated patients.
  • one aspect of this document features a method of treating a subject having a cancer, the method comprising administering successively, to the subject in need thereof, a first and second doses of engineered T-cells expressing a chimeric antigen receptor (CAR) (CAR-T cells), said CARs targeting specifically an antigen associated with the cancer,
  • CAR chimeric antigen receptor
  • the second dose of CAR-T cells is administered between 10 and 17 days after the first dose of CAR-T cells, such as after 10, 11, 12, 13, 14, 15, 16 or 17 days;
  • the subject has been preconditioned with a lymphodepleting treatment to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood;
  • no lymphodepleting treatment is administered between the first and second doses of CAR-T cells or concomitantly to the second dose of CAR-T cells; and/or for 28 days after the administration of the first dose of CAR-T cells.
  • Another aspect relates to a pharmaceutical composition
  • a pharmaceutical composition comprising one dose of CAR-T cells for use in the treatment of a subject having a cancer, according to a method as described herewith comprising administering successively a first and second doses of CAR-T cells, wherein said CAR targets specifically an antigen associated with the patient’s cancer.
  • a still other aspect relates to a combination of a pharmaceutical composition comprising a first dose of CAR-T cells and a pharmaceutical composition comprising a second dose of CAR-T cells, said CARs targeting, respectively, specifically an antigen associated with a cancer, for use in the treatment of a subject having said cancer, according to the method described above.
  • said methods and compositions for use refer to a pre-conditioning lymphodepleting treatment comprising a CD52-antibody such as alemtuzumab.
  • said methods and compositions for use make use of engineered allogeneic CAR-T cells which are CD52 negative and TCR negative.
  • CD123CAR specific chimeric antigen receptor
  • CAR specific chimeric antigen receptor
  • Embodiment 1 A method of treating a subject having a cancer, the method comprising administering successively, to the subject in need thereof, a first and second doses of engineered T-cells expressing a chimeric antigen receptor (CAR) (CAR-T cells), said CARs targeting specifically an antigen associated with the cancer,
  • CAR chimeric antigen receptor
  • the second dose of CAR-T cells is administered between 10 and 17 days after the first dose of CAR-T cells, such as after 10, 11, 12, 13, 14, 15, 16 or 17 days;
  • the subject has been preconditioned with a lymphodepleting treatment to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood;
  • no lymphodepleting treatment is administered between the first and second doses of CAR-T cells or concomitantly to the second dose of CAR-T cells; and/or for 28 days after the administration of the first dose of CAR-T cells;
  • Embodiment 2 The method according to embodiment 1, wherein said lymphodepleting treatment comprises administration of an anti-CD52 therapeutic antibody such as alemtuzumab.
  • Embodiment 3 The method according to any one of embodiments 1 to 2, wherein said lymphodepleting treatment comprises administration of fludarabine or cyclophosphamide.
  • Embodiment 4 The method according to any one of embodiments 1 to 3, wherein said lymphodepleting treatment comprises administration of fludarabine and cyclophosphamide.
  • Embodiment 5 The method according to embodiment 4, wherein said lymphodepleting treatment comprises administration of fludarabine, cyclophosphamide and alemtuzumab.
  • Embodiment 6 The method according to embodiment 5, wherein said lymphodepleting treatment comprises administration of:
  • - fludarabine at between about 1 and 100 mg/m 2 /day, between about 10 and 75 mg/m 2 /day, between about 15 and 50 mg/m 2 /day, between about 20 and 40 mg/m 2 /day, or about 25, 30 or 40 mg/m 2 /day, for 1, 2, 3, 4, or 5 days;
  • - cyclophosphamide at between about 50 and 10000 mg/m 2 /day, between 50 and 5 000 mg/m 2 /day, between 50 and 1000 mg/m 2 /day, between 100 and 1000 mg/m 2 /day, between 500 and 1000 mg/m 2 /day, between 600 and 800 mg/m 2 /day, or about 600, 650, 700, 750 or 800 mg/m 2 /day, for 1, 2, 3, or 4 days;
  • - alemtuzumab at between about 5 and 50 mg/day, between 10 and 40 mg/day, between 10 and 20 mg/day, or at 10, 11, 12, 13, 14, or 15 mg/day, for 1, 2, 3, 4, or 5 days.
  • Embodiment 7 The method according to embodiment 5 or embodiment 6, wherein said lymphodepleting treatment comprises administration of:
  • the first dose of CAR-T cells comprises between about 10 4 to about 10 8 CAR-T cells per kilogram body weight of the subject (cells/kg) and no more than 10 9 total CAR-T cells, or between about 10 5 to 10 9 total CAR-T cells;
  • the second dose of CAR-T cells comprises between about 10 4 to about 10 8 CAR-T cells per kilogram body weight of the subject (cells/kg) and no more than 10 9 total CAR-T cells, or between about 10 5 to 10 9 total CAR-T cells;
  • the antigen targeted by the CAR expressed by the CAR-T cells comprised in the first dose is identical or different from the antigen targeted by the CAR-T cells comprised in the second dose.
  • Embodiment 9 The method according to any one of embodiments 1 to 8, wherein said T- cells are primary T-cells.
  • Embodiment 10 The method according to embodiment 9, wherein said T-cells are cytotoxic T-lymphocyte and/or a helper T-lymphocytes.
  • Embodiment 11 The method according to any one of embodiments 9 to 10, wherein said primary T-cells originate from a human.
  • Embodiment 12 The method according to any one of embodiments 1 to 11, wherein said CAR-T cells are autologous with respect to the subject to be treated.
  • Embodiment 13 The method according to any one of embodiments 1 to 11, wherein said CAR-T cells are allogeneic with respect to the subject to be treated.
  • Embodiment 14 The method according to any one of embodiments 1 to 13, wherein said CAR-T cells have been genetically modified to confer resistance to at least one immune suppressive or chemotherapy drug.
  • Embodiment 15 The method according to any one of embodiments 1 to 14, wherein said CAR-T cells have been genetically modified to confer resistance to alemtuzumab.
  • Embodiment 16 The method according to embodiment 15, wherein said CAR-T cells have been genetically modified to suppress or repress expression of CD52 at the surface of said CAR-T cells.
  • Embodiment 17 The method according to any one of embodiments 1 to 16, wherein said CAR-T cells have been genetically modified to suppress or repress expression of at least one component of a T-Cell Receptor (TCR) at the surface of said CAR-T cell.
  • TCR T-Cell Receptor
  • Embodiment 18 The method according to any one of embodiments 1 to 17, wherein said CAR-T cells have been genetically modified to suppress or repress expression of a TCRa gene and/or a TCR0 gene.
  • Embodiment 19 The method according to any one of embodiments 1 to 18, wherein said CAR-T cells have at least one gene encoding TCR alpha, TCR beta, and/or CD3 that has been inactivated.
  • Embodiment 20 The method according to any one of embodiments 1 to 19, wherein said CAR-T cells have been genetically modified to suppress or repress expression of at least one gene encoding a MHC-I protein, such as 02m and HLA.
  • a MHC-I protein such as 02m and HLA.
  • Embodiment 21 The method according to any one of embodiments 1 to 20, wherein said CAR-T cells have a 02m gene that has been inactivated and have, integrated in their genome, an exogenous sequence encoding a NK inhibitor such as a HLA-E peptide fusion protein.
  • Embodiment 22 The method according to any one of embodiments 1 to 21, wherein said CAR-T cells have been genetically modified to suppress or repress expression of a gene encoding an immune checkpoint protein and/or a receptor thereof.
  • Embodiment 23 The method according to any one of embodiments 1 to 22, wherein said CAR-T cells have been genetically modified to comprise a suicide gene.
  • Embodiment 24 The method according to any one of embodiments 1 to 23, wherein said CAR-T cells are one or more of: CD52 negative, TCR negative, B2M negative, PDCD1 negative.
  • Embodiment 25 The method according to any one of embodiments 1 to 24, wherein said CAR-T cells are at least CD52 negative or at least CD52 and TCR negative.
  • Embodiment 26 The method according to any one of embodiments 1 to 25, wherein said cancer is an haematological cancer or a solid cancer.
  • Embodiment 27 The method according to any one of embodiments 1 to 26, wherein said cancer is a leukemia such as leukemia selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, melodysplastic syndrome, acute lymphoid leukemia, chronic lymphoid leukemia, and myelodysplastic syndrome.
  • leukemia selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, melodysplastic syndrome, acute lymphoid leukemia, chronic lymphoid leukemia, and myelodysplastic syndrome.
  • Embodiment 28 The method according to any one of embodiments 1 to 27, wherein said cancer is acute myelogenous leukemia (AML).
  • AML acute myelogenous leukemia
  • Embodiment 29 The method according to any one of embodiments 1 to 28, wherein at least one of said first dose and second dose of CAR-T cells comprises CAR-T cells expressing a CAR targeting an antigen selected from the group consisting of CD 123, CD38, CLL1, FLT3, CD7, FRbeta, CD33, LEY.
  • a CAR targeting an antigen selected from the group consisting of CD 123, CD38, CLL1, FLT3, CD7, FRbeta, CD33, LEY.
  • Embodiment 30 The method according to any one of embodiments 1 to 29, wherein at least one of said first dose and second dose of CAR-T cells comprises CAR-T cells expressing a CAR targeting CD 123.
  • Embodiment 31 The method according to any one of embodiments 1 to 30, wherein at least one of said first dose and second dose of CAR-T cells comprises CAR-T cells expressing a CAR targeting CD 123 having a polypeptide structure comprising an extra cellular ligand binding-domain comprising a heavy chain variable region (VH) and a light chain variable region (VL) from a monoclonal anti-CD123 antibody, a CD8a hinge, a CD8a transmembrane domain, and a cytoplasmic domain including a CD3 signaling domain and a co -stimulatory domain from 4-1BB, wherein said VH comprises the CDR sequences of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15 and said VL comprises the CDR sequences of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18.
  • VH heavy chain variable region
  • VL light chain variable region
  • Embodiment 32 The method according to embodiment 31, wherein said VH has at least 80% identity with SEQ ID NO: 11 and comprises the CDRs of amino acid sequences SEQ ID NO: 13 to SEQ ID NO: 15, and said VL has at least 80% identity with SEQ ID NO: 12 and comprises the CDRs of amino acid sequences SEQ ID NO: 16 to SEQ ID NO: 18.
  • Embodiment 32 The method according to embodiment 31 or embodiment 32, wherein said VH comprises the amino acid sequence of SEQ ID NO: 11 and said VL comprises the amino acid sequence of SEQ ID NO: 12.
  • Embodiment 33 The method according to any one of embodiments 31 to 33, wherein said CAR targeting CD 123 comprises an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 19, and comprises the CDRs of amino acid sequences SEQ ID NO: 13 to 18.
  • Figure 1 schematic representation of immunotherapy protocols following a single dose regimen (A) or a 2-dose regimen (B) as described herewith.
  • DLT Dose Limiting Toxicity
  • LD Lymphodepletion
  • EOT End Of Treatment.
  • Figure 2 Absolute lymphocyte counts measured by a complete cell count and differential (A), CAR-T expansion measured by qPCR (vector copy number/microgram DNA) in whole blood (B), percentage of blasts in bone marrow measured by flow cytometry (C), after a first dose of CAR-T cells administration following a preconditioning lymphodepleting treatment comprising fludarabine and cyclophosphamide.
  • Figure 3 Absolute lymphocyte counts measured by a complete cell count and differential (A), CAR-T expansion measured by qPCR (vector copy number/microgram DNA) in whole blood (B), percentage of blasts in bone marrow measured by flow cytometry (C), after a first dose of CAR-T cells administration following a preconditioning lymphodepleting treatment comprising fludarabine, cyclophosphamide and alemtuzumab.
  • FIG. 4 Cytokines secretion in patients having received a first dose of CAR-T cells after a preconditioning lymphodepleting treatment comprising fludarabine, cyclophosphamide and alemtuzumab.
  • This document provides methods and materials for use in a 2-dose regimen immunotherapy treatment, in particular a CAR-T based treatment of cancer, that enhances the efficacy of the treatment while avoiding additional toxicities.
  • This document provides methods for treating a cancer comprising administering successively two doses of engineered T-cells expressing a CAR targeting a cancer to a pre- conditioned subject who received a lymphodepleting treatment that allows depletion of the patient’s immune cells for at least 20 days, or at least 28 days, from the start of lymphodepletion treatment. It also provides compositions comprising a dose of CAR-T cells and combinations of compositions comprising a dose of CAR-T cells for use in said methods for treating a cancer.
  • the 2-dose regimen as described herewith could be advantageous, in terms of efficacy and toxicity, for treating patients having a cancer, over a single-dose regimen, possibly repeated 2 times, or a split-dosing regimen.
  • the effects of a 2-dose regimen in a method as described herewith could be analyzed as follows: after a preconditioning lymphodepleting treatment, the first dose of CAR-T cells has a debulking effect on the tumor and creates a microenvironment favorable for CAR-T cells expansion and activity, and the second dose of CAR-T cells, administered in the time-window when these favorable conditions are present and the patient’s own immune cells have not yet recovered, pursues the anti -tumor activity and removes the residual tumor so as to have more chances to achieve a complete response or stable disease in cancer patients treated according to the 2-dose regimen as described herewith.
  • the term “about” means plus or minus 10% of the numerical value of the number with which it is being used.
  • a "recipient" is a patient that receives a transplant, such as a transplant containing a population of engineered immune cells, e.g. T-cells.
  • the transplanted cells administered to a recipient may be, e.g. autologous, syngeneic, or allogeneic cells.
  • a "donor” is a mammal (e.g. a human) from which one or more cells are isolated prior to administration of the cells, or progeny thereof, into a recipient.
  • the one or more cells may be, e.g. a population of immune cells or hematopoietic stem cells to be engineered, expanded, enriched, or maintained according to the methods described herewith prior to administration of the cells or the progeny thereof into a recipient.
  • a “donor” is not the patient to be treated.
  • “Expansion” in the context of cells refers to the increase in the number of a characteristic cell type, or cell types, from an initial cell population of cells, which may or may not be identical.
  • the initial cells used for expansion may not be the same as the cells generated from expansion.
  • Cell population includes eukaryotic cells, such as mammalian, e.g. human, cells isolated from biological sources, for example, blood product or tissues.
  • a cell population can derive from more than one cell.
  • the term "pharmaceutical composition” refers to the active ingredient in combination with a pharmaceutically acceptable carrier and/or excipient e.g. a carrier and/or excipient commonly used in the pharmaceutical industry.
  • a pharmaceutically acceptable carrier and/or excipient e.g. a carrier and/or excipient commonly used in the pharmaceutical industry.
  • pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals, such as human beings, without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • administering refers to the placement of a compound, cell, or population of cells as disclosed herein into a subject by a method or route which results in at least partial delivery of the agent at a desired site.
  • routes of administration includes by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation.
  • the compositions described herein may be administered to a patient subcutaneously, intradermaly, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally.
  • compositions comprising the compounds or cells disclosed herein can be administered by any appropriate route which results in an effective treatment in the patient.
  • the compositions are administered by intravenous injection.
  • the patient who can be treated with the materials and methods disclosed herewith can be a mammal, including a human and a non-human primate.
  • nucleic acid or “polynucleotides” refers to nucleotides and/or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action.
  • Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g.
  • Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties.
  • Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters.
  • the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs.
  • Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes.
  • Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages.
  • Nucleic acids can be either single stranded or double stranded.
  • polypeptide peptide
  • protein protein
  • amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of corresponding naturally-occurring amino acids.
  • the terms “treat,” “treatment,” “treating,” and the like refer to obtaining a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
  • Treatment covers any treatment of a disease in a mammal (e.g.
  • a human includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, e.g. causing regression of the disease, e.g. to completely or partially remove symptoms of the disease.
  • subject or "patient” as used herein includes mammals including nonhuman primates and humans.
  • an “effective amount” or “therapeutically effective amount” refers to that amount of a composition described herein which, when administered to a subject (e.g. human), is sufficient to aid in treating a disease.
  • the amount of a composition that constitutes a “therapeutically effective amount” will vary depending on the cell preparations, the condition and its severity, the manner of administration, and the age of the subject to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
  • a therapeutically effective dose refers to that ingredient or composition alone.
  • a therapeutically effective dose refers to combined amounts of the active ingredients, compositions or both that result in the therapeutic effect, whether administered concurrently, simultaneously, or sequentially.
  • a vector is meant a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • a “vector” can include, but is not limited to, a viral vector, a plasmid, an oligonucleotide, a RNA vector or a linear or circular DNA or RNA molecule which may consist of a chromosomal, non-chromosomal, semisynthetic or synthetic nucleic acids.
  • Preferred vectors are those capable of autonomous replication (episomal vector) and/or expression of nucleic acids to which they are linked (expression vectors). Large numbers of suitable vectors are known to those of skill in the art and commercially available.
  • Viral vectors include retrovirus, adenovirus, parvovirus (e.g. adenoassociated viruses (AAV), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g. influenza virus), rhabdovirus (e.g. rabies and vesicular stomatitis virus), paramyxovirus (e.g.
  • RNA viruses such as picornavirus and alphavirus
  • double-stranded DNA viruses including adenovirus, herpesvirus (e.g. Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g. vaccinia, fowlpox and canarypox).
  • herpesvirus e.g. Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus
  • poxvirus e.g. vaccinia, fowlpox and canarypox
  • Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.
  • retroviruses examples include avian leukosis-sarcoma, mammalian C-type, B-type viruses, D type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
  • locus is the specific physical location of a DNA sequence (e.g. of a gene) into a genome.
  • locus can refer to the specific physical location of a rare-cutting endonuclease target sequence on a chromosome.
  • Such a locus can comprise a target sequence that is recognized and/or cleaved by a sequence-specific endonuclease as described herein. It is understood that the locus of interest can not only qualify a nucleic acid sequence that exists in the main body of genetic material (i.e. in a chromosome) of a cell but also a portion of genetic material that can exist independently to said main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting examples.
  • cleavage when used in reference to nucleic acid refers to the breakage of the covalent backbone of a polynucleotide. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. Double stranded DNA, RNA, or DNA RNA hybrid cleavage can result in the production of either blunt ends or staggered ends.
  • Sequence identity refers to the identity between two nucleic acid molecules or polypeptides. It refers to the residues in the two sequences which are the same when the sequences are aligned for maximum correspondence. When a position in the compared sequence is occupied by the same base (or amino acid), then the molecules are identical at that position.
  • a degree of identity between nucleic acid sequences (or amino acid sequences) is a function of the number of identical or matching nucleotides (or amino acids) at positions shared by the aligned nucleic acid sequences (or amino acid sequences).
  • polypeptides having at least 70%, 85%, 90%, 95%, 98% or 99% identity to specific polypeptides described herein and exhibiting substantially the same functions, as well as polynucleotide encoding such polypeptides, are contemplated.
  • this document provides a method of treating a subject having a cancer, the method comprising administering successively, to the subject in need thereof, a first and second doses of engineered T-cells expressing a chimeric antigen receptor (CAR) (CAR-T cells), said CARs targeting specifically an antigen associated with the cancer,
  • CAR chimeric antigen receptor
  • the second dose of CAR-T cells is administered between 10 and 17 days after the first dose of CAR-T cells, such as after 10, 11, 12, 13, 14, 15, 16 or 17 days;
  • the subject prior to the administration of the first dose of CAR-T cells, the subject has been preconditioned with a lymphodepleting treatment to eliminate, at least partially, the subject’s own immune cells to have, for at least 20 consecutive days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood; - wherein no lymphodepleting treatment is administered between the first and second doses of CAR-T cells or concomitantly to the second dose of CAR-T cells; and/or for 28 days after the administration of the first dose of CAR-T cells;
  • the subject prior to the administration of the first dose of CAR- T cells, has been preconditioned with a lymphodepleting treatment to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood.
  • compositions described herewith can use any type of immune cells, including T-cells, NK-cells, and macrophages.
  • the source of the engineered immune-cells (e.g. T-cells) useful in the methods described herewith is not particularly limiting.
  • the engineered immune cells originate from a healthy donor or from a patient diagnosed with cancer.
  • the source of the immune cells to be engineered are primary cells, and by “primary cell(s)” are intended cells taken directly from living tissue (e.g. biopsy material) and established for growth in vitro for a limited amount of time, meaning that they can undergo a limited number of population doublings.
  • Primary cells are opposed to continuous tumorigenic or artificially immortalized cell lines.
  • Primary immune cells can be obtained from a number of non-limiting sources, including peripheral blood mononuclear cells (PBMC), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and from tumors, such as tumor infiltrating lymphocytes.
  • PBMC peripheral blood mononuclear cells
  • Primary immune cells are collected from donors or patients through a variety of methods known in the art, as for instance by leukapheresis techniques as reviewed by Schwartz et al. (J. Clin. Apher. (2013), 28(3):145-284).
  • said immune cells e.g. T-cells
  • said immune cells are part of a mixed population of immune cells which present different phenotypic characteristics, such as comprising CD4, CD8 and/or CD56 positive cells.
  • the immune cells can derive from stem cells.
  • the stem cells can be adult stem cells, embryonic stem cells, such as non-human stem cells, cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells or hematopoietic stem cells.
  • Representative human cells are CD34+ cells.
  • the immune cells derived from stem cells such as those deriving from induced pluripotent stem cells (iPSCs) (Yamanaka et al. (2008) Science. 322 (5903): 949-53) are also regarded as primary immune cells.
  • Lentiviral expression of reprogramming factors has been used to induce multipotent cells from human peripheral blood cells (Staerk et al. (2010) Cell stem cell. 7 (1): 20-4 ; Loh et al. (2010) Cell stem cell. 7 (1): 15-9).
  • the immune cells can be derived from human embryonic stem cells by techniques well known in the art that do not involve the destruction of human embryos (Chung et al. (2008) Cell Stem Cell 2(2): 113-117).
  • the engineered immune cells are T-cells and can be cytotoxic T- lymphocytes or helper T-lymphocytes.
  • the immune-cells e.g. T-cells
  • the immune-cells are allogeneic.
  • allogeneic is meant that the cells originate from a donor or are produced and/or differentiated from stem cells in view of being infused into patients having a different haplotype.
  • Such immune cells are generally engineered to be less allor eactive and/or become more persistent with respect to their patient host.
  • the method of engineering the allogeneic cells can comprise the step of reducing or inactivating TCR expression into T-cells, or into the stem cells to be derived into T-cells.
  • sequence-specific reagents such as by gene silencing or gene editing techniques by using for instance nucleases, base editing techniques, shRNA and RNAi as non-limited examples.
  • cells originating from the patient who will receive the engineered cells as part of an immunotherapy treatment are said to be “autologous” with respect to said patient.
  • the engineered immune-cells useful in the methods and compositions described herewith can be engineered ex-vivo to modify their immune specificity in order to perform adoptive immunotherapy, improve their anti-tumoral activity, reduce their immunogenicity, increase their persistence, and/or suppress their activity if necessitated by serious side-effects or threat to the patient’s life.
  • the cells can be genetically modified by using viral vectors and/or transient expression of rare-cutting endonucleases to introduce transgenes or inactivate endogenous genes as further described in the present specification. These techniques have been extensively reviewed in the art, like for instance by Maeder et al (Molecular Therapy (2016) 24(3): 430-446).
  • a gene can be inactivated or repressed by using rare-cutting endonuclease able to selectively inactivate by DNA cleavage that gene locus.
  • rare- cutting endonuclease may be a TALE-nuclease, meganuclease, zing-finger nuclease (ZFN), or RNA guided endonuclease (such as Cas9).
  • a gene’s expression can also be inhibited or repressed by using (e.g. introducing into the T-cell) a nucleic acid molecule that specifically hybridizes (e.g. binds) under cellular conditions with the cellular mRNA and/or genomic DNA corresponding to that gene, thereby inhibiting transcription and/or translation of the gene.
  • the inhibition of expression a gene can be achieved by using (e.g. introducing into the T-cell) an antisense oligonucleotide, small interfering (siRNA), or short hairpin RNA (shRNA).
  • the cells can be genetically engineered by using methylases, exonucleases, histone deacetylases, end-processing enzymes such as exonucleases, and more particularly cytidine deaminases such as those coupled with the CRISPR/cas9 system to perform base editing (i.e. nucleotide substitution) without necessarily resorting to cleavage by nucleases as described for instance by Hess et al. (Mol Cell. (2017) 68(1): 26- 43) and Rees et al. (Nat. Rev. Genet. (2016) 19, 770-788).
  • base editing i.e. nucleotide substitution
  • gene editing can be performed using a sequence-specific nuclease reagent, such as a sequence-specific endonuclease like a rare-cutting endonuclease like TALE Nuclease, or a RNA guide coupled with a guided endonuclease like CRISPR.
  • a sequence-specific nuclease reagent such as a sequence-specific endonuclease like a rare-cutting endonuclease like TALE Nuclease, or a RNA guide coupled with a guided endonuclease like CRISPR.
  • sequence-specific nuclease reagent include reagents that have nickase or endonuclease activity.
  • the sequence-specific nuclease reagent can be a chimeric polypeptide comprising a DNA binding domain and another domain displaying catalytic activity.
  • catalytic activity can be for instance a nuclease to perform gene inactivation, or nickase or double nickase to preferentially perform gene insertion by creating cohesive ends to facilitate gene integration by homologous recombination.
  • nuclease generally refers to any wild-type or variant enzyme capable of catalyzing the hydrolysis (cleavage) of bonds between nucleic acids within a DNA or RNA molecule, a DNA molecule. Endonucleases (and, thus, sequence-specific endonucleases) do not cleave the DNA or RNA molecule irrespective of its sequence but recognize and cleave the DNA or RNA molecule at specific polynucleotide sequences, further referred to as “target sequences” or “target sites”.
  • Endonucleases can be classified as rare-cutting endonucleases when having typically a polynucleotide recognition site greater than 10 base pairs (bp) in length, or of 14-55 bp. Rare-cutting endonucleases significantly increase homologous recombination by inducing DNA double-strand breaks (DSBs) at a defined locus thereby allowing gene repair or gene insertion therapies (Pingoud and Silva (2007) Nat. Biotechnol. 25(7): 743-4).
  • DSBs DNA double-strand breaks
  • sequence specific-reagent can be a base editor able to perform base editing as described for instance in Komor eta/. (Nature (2019) 533(7603), 420-424) and in Mok et al. (Nature (2020) 583:631-637).
  • base editor refers to a catalytic domain capable of making a modification to a base (e.g. A, T, C, G, or U) within a nucleic acid sequence by converting one base to another (e.g. A to G, A to C, A to T, C to T C to G, C to A, G to A, G to C, G to T, T to A, T to C, T to G).
  • Base editors can include cytidine deaminases that convert target C/G to T/A and adenine base editors that convert target A/T to G/C.
  • Adenosine deaminase can be, for instance, TadA or its variant TadA7.10 as described by Jeong etal. (Nat Biotechnol (2021) 39, 1426-1433).
  • Different members of Apolipoprotein B mRNA editing enzyme (APOBEC) family can be used to convert cytidines to thymidines, such as the murine rAPOBECl and the human APOBEC3G as developed by Lee et al. (Science Advances (2020) 6(29)).
  • sequence specific-reagents as defined herewith include TALE-base editors (BE), which can be generated by the fusion of transcription activator-like effector array proteins (TALE) with a base editor catalytic domain.
  • the base editor catalytic domain can be a double-stranded DNA deaminase (“DddA”) that precisely makes nucleotide changes and/or corrects pathogenic mutations, rather than destroying DNA by double-strand breaks (DSBs).
  • DddA double-stranded DNA deaminase
  • DSBs double-strand breaks
  • such TALE-base editors can also comprise a domain that inhibits uracil glycosylase referred to as “UGI”, and/or a nuclear localization signal.
  • uracil glycosylase inhibitor or “UGI,” as used herein, refers to a protein that is capable of inhibiting an uracil-DNA glycosylase base-excision repair enzyme.
  • a UGI domain can comprise a wild-type UGI or a canonical UGI.
  • the UGI proteins can include fragments of UGI and proteins homologous to a UGI or a UGI fragment, which are useful to improve the specificity of base editing performed at a predetermined locus.
  • the engineered immune cells useful in the methods described herewith comprise an exogenous nucleic acid sequence encoding a recombinant TCR or a chimeric antigen receptor (CAR) targeting specifically an antigen associated with a tumor or cancer (also referred herewith as “tumor antigen”).
  • the engineered immune cells can express a recombinant TCR or a chimeric antigen receptor (CAR) specific for a tumor antigen, such as a tumor antigen associated with AML.
  • the engineered immune cells useful in the methods and compositions for use described herewith express a CAR at their cell surface and comprise an exogenous sequence, stably inserted into their genome, encoding said CAR.
  • recombinant TCR an artificially modified T-cell receptor in which at least one of the TCR components is obtained by expression of an exogenous polynucleotide.
  • the intracellular signalling domain of a recombinant TCR can be derived from the cytoplasmic part of a membrane bound receptor to induce cellular activation, e.g., the Fc epsilon RI receptor gamma-chain or the CD3 zeta-chain.
  • a recombinant TCR After introduction of the exogenous polynucleotide encoding a TCR in an immune cell, the recombinant TCR partially or completely replaces the expression of the endogenous TCR in said cell. In some cases, a recombinant TCR recognizes a tumor- expressed peptide/MHC complex. In some cases, a recombinant TCR a/p comprises an extracellular ligand binding domain and a transmembrane domain without stimulatory and/or co -stimulatory domain. Indeed, typically, recombinant TCR a/p do not contain activation or costimulation domains as they depend on endogenous CD3 chains for activation and endogenous CD28 for costimulation.
  • chimeric antigen receptor or “CAR” is generally meant a synthetic receptor comprising a targeting moiety (also called “binding moiety”) that is associated with one or more signaling domains in a single fusion molecule.
  • a targeting moiety also called “binding moiety”
  • the term “chimeric antigen receptor” covers single chain CARs as well as multi-chain CARs.
  • the binding moiety of a CAR can comprise an antigen-binding domain of a single-chain antibody (scFv), comprising light chain and heavy chain variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully.
  • the signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains.
  • First generation CARs have been shown to successfully redirect T-cell cytotoxicity. However, they failed to provide prolonged expansion and anti -tumor activity in vivo.
  • Signaling domains from co-stimulatory molecules including CD28, OX- 40 (CD134), and 4-1BB (CD137) have been added alone (second generation) or in combination (third generation) to enhance survival and increase proliferation of CAR modified T-cells.
  • CARs are not necessarily only single chain polypeptides, as multi-chain CARs are also possible.
  • the signalling domains and co-stimulatory domains are located on different polypeptide chains.
  • Such multi-chain CARs can be derived from FcsRI, by replacing the high affinity IgE binding domain of FcsRI alpha chain by an extracellular ligand-binding domain such as scFv, whereas the N- and/or C-termini tails of FcsRI beta and/or gamma chains are fused to signal transducing domains and co- stimulatory domains, respectively.
  • the extracellular ligand binding domain has the role of redirecting the immune cell (e.g.
  • CARs are generally expressed in effector immune cells to redirect their immune activity against antigens expressed at the surface of tumor cells from various malignancies including lymphomas and solid tumors.
  • a component of a CAR is any functional subunit of a CAR that is encoded by an exogenous polynucleotide sequence introduced into the cell. For instance, this component can help the interaction with the target antigen, the stability or the localization of the CAR into the cell.
  • a nucleic acid that can be used to engineer the immune cells generally encodes a CAR comprising: an extracellular antigen -binding domain that binds to a tumor antigen, a hinge, a transmembrane domain, and an intracellular domain comprising a stimulatory domain and/or a primary signalling domain.
  • the extracellular antigen-binding domain is a scFv comprising a Heavy variable chain (VH) and a Light variable chain (VL) of an antibody binding to a tumor antigen connected via a Linker.
  • the extracellular antigen-binding domain can also derive from a single domain antibody (e.g.
  • the extracellular antigen-binding domain can comprise one Heavy variable chain and no Light variable chain.
  • Walser et al. (Viruses (2022): 14, 2242) describe ankyrin repeat domains.
  • the transmembrane domain can be, for example, a CD8a transmembrane domain, a CD28 transmembrane domain, or a 4- IBB transmembrane domain.
  • the co-stimulatory domain can be, for example, the 4-1 BB co-stimulatory domain or CD28 co-stimulatory domain.
  • the primary signalling domain can be, for example, the CD3 ⁇ signalling domain.
  • the CARs expressed by the engineered immune cells described herewith can also comprise a signal peptide to direct the nascent protein to the endoplasmic reticulum and subsequent expression at the engineered cell’s surface.
  • the signal peptide is cleaved after addressing the CAR to the cell surface.
  • Table 1 presents sequences of different domains typically present in a CAR.
  • a tumor-CAR as well as a tumor-TCR, comprises an extracellular ligand (or antigen) binding domain that recognizes a tumor antigen.
  • a tumor-CAR and a tumor-TCR as described herewith comprise an extracellular tumor antigen-binding domain.
  • extracellular antigen binding domain or “extracellular ligand binding domain” as used herein generally refers to an oligopeptide or polypeptide that is capable of binding a specific antigen, such as a tumor antigen. In some cases, the domain will be capable of interacting with a cell surface molecule, such as a ligand. For example, in some cases, an extracellular antigen-binding domain can be chosen to recognize an antigen that acts as a cell surface marker on target cells associated with a particular disease state.
  • said extracellular antigen-binding domain can comprise a single chain antibody fragment (scFv) comprising the heavy (VH) and the light (VL) variable fragments of a target-antigen-specific monoclonal antibody joined by a flexible linker.
  • the antigen binding domain of a CAR expressed on the cell surface of the engineered cells described herein can be any domain that binds to the target antigen and that derives from, for example, a monoclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, and a functional fragment thereof.
  • tumor antigen is meant to cover “tumor-specific antigen”, “tumor associated antigen” and “antigen associated with a cancer”.
  • TSA Tumor- Specific Antigens
  • TAA Tumor- Associated Antigens
  • Tumor antigen also refers to mutated forms of a protein, which only appears in that form in tumors, while the non-mutated form is observed in non-tumoral tissues.
  • a tumor antigen can be an antigen specific of, or associated with, a tumor or cancer, including haematological cancers and solid tumors.
  • said engineered immune cells express a chimeric antigen receptor (CAR), or recombinant TCR, specific for a tumor antigen selected from the group consisting of CD7, CD25, CD30, CD33, CD34, CD37, CD38, CD47, CD56, CD98, CD117, CD 123, CD 133, CD 157, FLT3, CLL1, c-kit, MUC1, CXCR4, VEGF, NKG2D F, folate receptor beta (FR beta), hepatocyte growth factor (HGF), HLA-A2 and Lewis Y.
  • CAR chimeric antigen receptor
  • TCR tumor antigen selected from the group consisting of CD7, CD25, CD30, CD33, CD34, CD37, CD38, CD47, CD56, CD98, CD117, CD 123, CD 133, CD 157, FLT3, CLL1, c-kit, MUC1, CXCR4, VEGF, NKG2D F, folate receptor beta (FR beta), hepatocyte growth factor (
  • said engineered immune cells express a chimeric antigen receptor (CAR), or recombinant TCR, specific for a tumor antigen selected from the group consisting of CD123, CD38, CLL1, FLT3, CD7, FRbeta, CD33, LEY.
  • CAR chimeric antigen receptor
  • TCR tumor antigen
  • the tumor antigen is selected from the group consisting of CD 123, CD22, and CD 19.
  • said engineered immune cells e.g. T-cells, express a chimeric antigen receptor (CAR) specific for CD 123, referred herewith as “CD123CAR” or “CAR123”.
  • CD123CAR chimeric antigen receptor
  • a CD123CAR can comprise an extra cellular ligand binding-domain comprising VH and VL from a monoclonal anti-CD123 antibody, a hinge, a transmembrane domain, a cytoplasmic domain including a CD3 zeta signaling domain and a co -stimulatory domain from 4-1 BB.
  • a CD123CAR can be one described in W02020/007593.
  • a CAR targeting CD 123 can have a polypeptide structure comprising an extra cellular ligand binding-domain comprising a heavy chain variable region (VH) and a light chain variable region (VL) from a monoclonal anti-CD123 antibody, a CD8a hinge, a CD8a transmembrane domain, and a cytoplasmic domain including a CD3 signaling domain and a co-stimulatory domain from 4- IBB, wherein said VH comprises the CDRs of amino acid sequences SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15 and said VL comprises the CDRs of amino acid sequences SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18.
  • VH heavy chain variable region
  • VL light chain variable region
  • a CD123CAR can have VH and VL having at least 80%, 85%, 90%, 95%, or at least 99% identity with SEQ ID NO: 11 and SEQ ID NO: 12, respectively, and comprising the CDRs of amino acid sequences SEQ ID NO: 13 to SEQ ID NO: 15 and SEQ ID NO: 16 to SEQ ID NO: 18, respectively.
  • said VH comprises the amino acid sequence of SEQ ID NO: 11 and said VL comprises the amino acid sequence of SEQ ID NO: 12.
  • said CAR targeting CD 123 can comprise an amino acid sequence having at least 80%, 85%, 90%, 95%, or at least 99% identity with SEQ ID NO: 19, and comprises the CDRs of amino acid sequences SEQ ID NO: 13 to SEQ ID NO: 18.
  • the CARs expressed by the engineered T-cells described herewith can comprise humanized versions of the VH and VL regions from murine monoclonal antibodies.
  • said CD8a hinge comprises an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 4.
  • said CD8a transmembrane comprises an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 6.
  • said CD3 ⁇ signaling domain comprises an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 9.
  • said co -stimulatory domain from 4-1 BB comprises an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 8.
  • sequence of the CAR targeting CD 123 that can be expressed by the engineered CAR-T cells useful in the methods and compositions described herewith is as follows:
  • said CAR targeting CD123 can comprise an additional sequence comprising 2 epitopes specifically recognized by Rituximab (referred as R2) allowing the immune depletion of the engineered CAR positive immune cells as described for instance in W02016120216.
  • R2 Rituximab
  • the engineered immune cells e.g. T-cells
  • the engineered immune cells that have been modified to express a CAR or recombinant TCR targeting an antigen associated with a cancer can have one or more additional modifications.
  • the engineered T-cells can comprise an inactivated T-cell receptor (TCR) and can have been modified by inactivating at least one component of the TCR, e.g. by using a sequence-specific endonuclease such as a RNA guided endonuclease associated with a specific guide RNA, or using other gene editing approaches such as TALE-nucleases.
  • TCR T-cell receptor
  • T cell receptors are cell surface receptors that participate in the activation of T-cells in response to the presentation of antigen.
  • the TCR is generally made from two chains, alpha and beta, which assemble to form a heterodimer and associates with the CD3- transducing subunits to form the T-cell receptor complex present on the cell surface.
  • Each alpha and beta chain of the TCR consists of an immunoglobulin-like N-terminal variable (V) and constant (C) region, a hydrophobic transmembrane domain, and a short cytoplasmic region.
  • variable region of the alpha and beta chains are generated by V(D)J recombination, creating a large diversity of antigen specificities within the population of T-cells.
  • T-cells are activated by processed peptide fragments in association with an MHC molecule, introducing an extra dimension to antigen recognition by T-cells, known as MHC restriction.
  • MHC restriction Recognition of MHC disparities between the donor and recipient through the T cell receptor leads to T-cell proliferation and the potential development of GvHD. It has been shown that normal surface expression of the TCR depends on the coordinated synthesis and assembly of all seven components of the complex (Ashwell and Klusner (1990) Annu. Rev. Immunol.
  • TRAC encoding TCRalpha constant domain
  • TRBC encoding TCRbeta constant domain
  • At least 50%, at least 70%, at least 90%, or at least 95% of the engineered T-cells in the population useful in the methods described herewith are mutated in their TRAC, TRBC and/or CD3 alleles.
  • the TCR can be inactivated by using specific TALE-nucleases, better known under the trademark TALEN® (Cellectis, 8, rue de la Croix Jarry, 75013 PARIS).
  • TALE-nucleases better known under the trademark TALEN® (Cellectis, 8, rue de la Croix Jarry, 75013 PARIS). This method has proven to be highly efficient in primary cells using RNA transfection as part of a platform allowing the mass production of allogeneic T-cells. See, e.g. WO 2013/176915, which is incorporated by reference herein in its entirety.
  • the TCR can be inactivated using an RNA guided endonuclease associated with a specific guide RNA.
  • U.S. Patent No. 10,870,864 describes methods for inactivating a TCR in cells using such methods, which is incorporated by reference herein. Engraftment of allogeneic T-cells is possible by inactivating at least one gene encoding a TCR component. In some cases, the TCR is rendered not functional in the cells by inactivating a TRAC gene and/or a TCRB gene. TCR inactivation in allogeneic T-cells aims to prevent or reduce GvHD.
  • the TCR gene can be inactivated by inserting into the TRAC locus of the cell’s genome at least one exogenous polynucleotide encoding a tumor-CAR.
  • the TCR gene can be inactivated as described in Example 1 of WO 2020/007593, by electroporating the cells with mRNA encoding the two halves of the TALE-nuclease targeting the TRAC region of SEQ ID NO: 28, where the 2 half-nucleases have the amino acid sequence of SEQ ID NO: 24 and SEQ ID NO: 25, respectively.
  • TALE-nuclease The characteristics of a TALE-nuclease that can be used to inactivate the CD52 gene in the cells are provided in Table 2.
  • inactivating a gene it is intended that the gene of interest is not expressed in a functional protein form and/or not presented at the cell’s surface in the case of membrane protein.
  • the engineered immune cells e.g. T-cells
  • the engineered immune cells can be modified to confer resistance to at least one immune suppressive and/or chemotherapy drug that may be used as pre-conditioning treatment. This aims at improving cancer therapy and selective engraftment of the transferred cells.
  • the engineered cells are advantageously genetically modified to have their CD52 inactivated or repressed, as described for instance in WO 2013/176915.
  • the CD52 gene can be inactivated for instance as described in Example 2 of WO 2020/007593, by electroporating the cells with mRNA encoding the two halves of the TALE-nuclease targeting the CD52 region of SEQ ID NO: 29, where the 2 half-nucleases have the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 27, respectively.
  • TALE-nuclease The characteristics of a TALE-nuclease that can be used to inactivate the CD 52 gene in the cells are provided in Table 3.
  • the engineered cells are advantageously genetically modified to have a FKBP family gene member such as FKBP 12 or a variant thereof inactivated or repressed.
  • the engineered cells are advantageously genetically modified to have a cyclophilin family gene member or a variant thereof inactivated or repressed.
  • the engineered immune cell can be further modified to confer resistance to a chemotherapy drug, such as a purine analogue drug, for example by inactivating DCK as described in WO 2015/75195.
  • a chemotherapy drug such as a purine analogue drug
  • Cytokine Release Syndrome is the most common adverse event of CAR-T cell therapy.
  • CRS is defined as a clinical syndrome that may occur after cell therapy due to the release of cytokines (substances secreted by immune cells) into the body’s blood stream. It has been shown that inactivation of Granulocyte-macrophage colonystimulating factor (GM-CSF) can prevent monocyte-dependent release of key cytokine release syndrome mediators (Sachdeva et al. (2019) J. Biol. Chem. 294(14) 5430-5437).
  • GM-CSF Granulocyte-macrophage colonystimulating factor
  • the engineered immune cells useful in the methods and compositions as described herewith can be genetically modified to suppress expression, or cell surface presentation, of GM-CSF.
  • the engineered cells can be modified to improve their persistence or lifespan into the patient, for instance by inactivating a gene encoding MHC-I component(s) such as HLA or B2M, such as described in WO 2015/136001 or by Liu et al. (2017, Cell Res 27:154-157).
  • MHC-I component(s) such as HLA or B2M
  • Beta-2 microglobulin also known as 02m, is the light chain of MHC class I molecules, and as such an integral part of the major histocompatibility complex. In human, 02m is encoded by the B2M gene.
  • inhibition of expression of B2M can be achieved by a genome modification, such as through the expression in the cell of a rare-cutting endonuclease able to selectively inactivate by DNA cleavage the B2M gene (e.g. human B2M gene, NCBI Reference Sequence: NG 012920.1).
  • a rare-cutting endonuclease may be a TALE- nuclease, meganuclease, zing-finger nuclease (ZFN), or RNA guided endonuclease (such as Cas9).
  • the B2M gene can be inactivated using TALE-nucleases as described in Example 3 of WO 2020/007593.
  • inhibition of expression of B2M can be achieved by using (e.g. introducing into the T-cell) a nucleic acid molecule that specifically hybridizes (e.g. binds) under cellular conditions with the cellular mRNA and/or genomic DNA encoding 02m, thereby inhibiting transcription and/or translation of the gene.
  • the inhibition of expression of B2M can be achieved by using (e.g. introducing into the T-cell) an antisense oligonucleotide, ribozyme or interfering RNA (RNAi) molecule.
  • such nucleic acid molecule can comprise at least 10 consecutive nucleotides of the complement of the mRNA encoding human 02m.
  • CIITA is the gene encoding class II major histocompatibility complex transactivator protein.
  • engineered immune cells e.g. T-cells
  • T-cells which have been inactivated in at least one gene selected from the group consisting of RFXANK, RFX5, RFXAP, TAPI, TAP2, ZXDA, ZXDB and ZXDC.
  • Inactivation may, for instance, be achieved by using a genome modification, such as through the expression in the cell of a rare-cutting endonuclease able to selectively inactivate, by DNA cleavage, a gene selected from the group consisting of RFXANK, RFX5, RFXAP, TAPI, TAP2, ZXDA, ZXDB and ZXDC.
  • a genome modification such as through the expression in the cell of a rare-cutting endonuclease able to selectively inactivate, by DNA cleavage, a gene selected from the group consisting of RFXANK, RFX5, RFXAP, TAPI, TAP2, ZXDA, ZX
  • engineered immune cells e.g. T-cells
  • T-cells which have a 02m gene that has been inactivated and have, integrated in their genome, an exogenous sequence encoding a NK inhibitor such as a HLA-E peptide fusion protein, for instance as disclosed in example 5 of WO 2020/007593.
  • T-cells Useful in the methods and compositions described herewith are engineered immune cells, e.g. T-cells, which have been genetically modified to suppress or repress expression of an immune checkpoint protein and/or the receptor thereof, in said cells, such as PDCD1 or CTLA4 as described in WO 2014/184744.
  • T-cells which are one or more of: CD52 negative, TCR negative, B2M negative, CIITA negative, PDCD1 negative, GM-CSF negative; CTLA4 negative, dCK negative.
  • the engineered immune cells e.g. T-cells
  • the engineered immune cells can be at least CD52- negative and TCR negative, or at least CD52-negative and B2M-negative.
  • the engineered immune cells e.g. T-cells, as described herewith do not present at their cell surface the antigen targeted by the tumor- CAR.
  • the engineered immune cells can be modified to comprise a suicide gene and/or a marker for cell sorting.
  • the engineered cells useful in the methods and compositions described herewith can comprise at their cell surface a CAR as described herewith, and at least one suicide domain (R)n (where R is a CD20 epitope recognized by Rituximab, and n is comprised between, and including, 0 to 10) and/or (Q)m (where Q is a CD34 epitope recognized by QBEN10, and m is comprised between, and including, 0 to 10), such as a region comprising 2 epitopes recognized by Rituximab and 1 epitope recognized by QBEN10 (referred to as “RQR8”) for cell depletion and/or cell sorting.
  • CD20 epitope recognized by Rituximab CPYSNPSLC (SEQ ID NO: 21).
  • CD34 epitope recognized by QBEND10 ELPTQGTFSNVSTNVSPAKPTTTA (SEQ ID NO: 22).
  • the engineered cells useful in the methods and compositions described herewith can comprise at their cell surface a CAR as described herewith, and a suicide domain having an amino acid sequence comprising SEQ ID NO: 23.
  • the engineered cells comprise a polynucleotide encoding a CAR as described herewith and a suicide domain arranged in a polycistronic arrangement where both of the 2 transcription units are controlled by a unique promoter, have the same direction of transcription and are separated by a “self-cleaving” peptide such as a 2A peptide (e.g. P2A, T2A, E2A, F2A).
  • a 2A peptide e.g. P2A, T2A, E2A, F2A
  • Methods of treatment comprising administration of CAR-T cells according to a 2- dose regimen
  • lymphodepleting conditioning regimen prior to adoptive cell transfer dramatically improves the efficacy of T-cell therapy. Without willing to be bound by theory, it is believed that lymphodepleting conditioning regimen works by multiple mechanisms, including eliminating sinks for homeostatic cytokines (such as IL-2, IL-7, and IL- 15), eradicating immunosuppressive elements (such as regulatory T cells and myeloid-derived suppressor cells), inducing costimulatory molecules and downregulating indoleamine 2,3- dioxygenase in tumor cells, and promoting expansion, function, and persistence of adoptively transferred T cells (Muranski et al. (2006) Nat. Clin. Pract. Oncol. 3(12):668- 681 ; Gattinoni et al. (2005) J. Exp. Med. 202(7): 907 -912 ; Ninomiya et al. (2015) Blood. 125(25):3905-3916).
  • homeostatic cytokines such as IL-2, IL-7
  • pre-conditioning lymphodepleting agents also called immunosuppressive agents, to reduce or eliminate the patient’s immune cells and improve CAR T-cell expansion and persistence.
  • the pre-conditioning lymphodepleting treatment can be combined with a pre-conditioning chemotherapeutic agent, for example, to reduce tumor burden prior to administration of the engineered T- cells.
  • the lymphodepleting agent has the effect of both a lymphodepleting agent and a chemotherapeutic agent, i.e. by reducing the patient’s immune cells number and by, at least partially, reducing tumor burden.
  • the lymphodepleting treatment aims to eliminate, at least partially, the subject’s own immune cells to have, for at least 20 consecutive days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood. In some cases, the lymphodepleting treatment allows to have less than about 200, or less than about 100, or less than about 10, or about 0 absolute lymphocyte counts per pl of subject’s whole blood, for at least 20 consecutive days.
  • the lymphodepleting treatment referred to in the methods described herewith eliminates, at least partially, the subject’s own immune cells to have less than 500 absolute lymphocyte counts per pl of subject’s whole blood, for at least 20, at least 25, at least 26, at least 27, or at least 28 consecutive days.
  • the lymphodepleting treatment referred to in the methods described herewith eliminates, at least partially, the subject’s own immune cells to have less than about 200, or less than about 100, or less than about 10, or about 0 absolute lymphocyte counts per pl of subject’s whole blood, for at least 20, at least 25, at least 26, at least 27, or at least 28 consecutive days.
  • the lymphodepleting treatment aims to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood.
  • the lymphodepleting treatment allows to have absolute lymphocyte counts per pl of subject’s whole blood of less than about 200, or of less than about 100, or of about 0 for at least 20 days.
  • Absolute lymphocyte counts in a subject’s whole blood sample are measured by a complete cell count and differential as, for instance, described by George-Gay et al. (J Perianesth Nurs, 2003, 18(2):96-114).
  • the lymphodepleting treatment comprises fludarabine, alone or in combination with another immunosuppressive agent.
  • the lymphodepleting treatment comprises cyclophosphamide, alone or in combination with another immunosuppressive agent.
  • the lymphodepleting treatment comprises an anti-CD52 antibody, such as alemtuzumab, alone or in combination with another immunosuppressive agent.
  • the lymphodepleting treatment comprises an anti-CD52 antibody, such as alemtuzumab, in combination with fludarabine.
  • the lymphodepleting treatment comprises an anti-CD52 antibody, such as alemtuzumab, in combination with cyclophosphamide.
  • the lymphodepleting treatment comprises an anti-CD52 antibody, such as alemtuzumab, in combination with cyclophosphamide and fludarabine.
  • an anti-CD52 antibody such as alemtuzumab
  • the lymphodepleting treatment comprises administration of fludarabine, cyclophosphamide and alemtuzumab.
  • a lymphodepleting treatment comprising administration of fludarabine, cyclophosphamide and alemtuzumab generally allows a sustained and prolonged low level (inferior or equal to about 500 absolute lymphocyte counts per pl of subject’s whole blood) of lymphocytes in the patient’s whole blood, for at least 20, at least 25, or at least 28 consecutive days.
  • the lymphodepletion treatment can comprise bendamustine.
  • the lymphodepletion treatment can comprise bendamustine and fludarabine, for instance bendamustine at about 70 mg/m 2 /day and fludarabine at about 30 mg/m 2 /day, for 3 days.
  • the lymphodepleting treatment can comprise bendamustine and alemtuzumab.
  • the lymphodepleting treatment can comprise a calcineurin inhibitor, a target of rapamycin, an interleukin-2alpha-chain blocker, an inhibitor of inosine monophosphate dehydrogenase, an inhibitor of dihydrofolic acid reductase, a corticosteroid such as dexamethasone, cyclosporine, or an immunosuppressive antimetabolite.
  • the lymphodepleting agent can be administered in a single dose or can be administered in a plurality of doses, such as given daily, every other day or every three days.
  • the lymphodepleting treatment may, for instance, comprise administration of fludarabine once daily for 1, 2, 3, 4, or 5 days, administration of cyclophosphamide once daily for 1, 2, 3, or 4 days, and administration of alemtuzumab once daily for 1, 2, 3, 4, or 5 days.
  • the lymphodepleting treatment can comprise administration of fludarabine at between about 1 and 100 mg/m 2 /day, between about 10 and 75 mg/m 2 /day, between about 15 and 50 mg/m 2 /day, between about 20 and 40 mg/m 2 /day, or about 25, 30 or 40 mg/m 2 /day; administration of cyclophosphamide at between about 50 and 10 000 mg/m 2 /day, between 100 and 1000 mg/m 2 /day, between 500 and 1000 mg/m 2 /day, between 600 and 800 mg/m 2 /day, or about 600, 650, 700, 750 or 800 mg/m 2 /day; and/or administration of alemtuzumab at between about 0.1 to 0.5 mg/kg/day, between 0.15 and 0.2 mg/kg/day, or about 0.15 mg/kg/day.
  • alemtuzumab is administered at a fixed dose comprised between about 5 and 50 mg/day, between 10 and 40 mg/day, between 10 and
  • the maximum daily dose of fludarabine is from 50 to 70 mg, e.g. about 60 mg
  • the maximum daily dose of cyclophosphamide is from 1 to 1.5 g, from 1.3 to 1.4 g, e.g. about 1.33 g
  • the maximum daily dose of alemtuzumab is from 10 to 15 mg, e.g. about 12 or 13 mg.
  • the lymphodepleting treatment comprises administration of:
  • - fludarabine at between about 1 and 100 mg/m 2 /day, between about 10 and 75 mg/m 2 /day, between about 15 and 50 mg/m 2 /day, between about 20 and 40 mg/m 2 /day, or about 25, 30 or 40 mg/m 2 /day, for 1, 2, 3, 4, or 5 days;
  • - cyclophosphamide at between about 50 and 10000 mg/ m 2 /day, between 50 and 5 000 mg/ m 2 /day, between 50 and 1000 mg/ m 2 /day, between 100 and 1000 mg/m 2 /day, between 500 and 1000 mg/ m 2 /day, between 600 and 800 mg/m 2 /day, or about 600, 650, 700, 750 or 800 mg/m 2 /day, for 1, 2, 3, or 4 days;
  • - alemtuzumab at between about 5 and 50 mg/day, between 10 and 40 mg/day, between 10 and 20 mg/day, or at 10, 11, 12, 13, 14, or 15 mg/day, for 1, 2, 3, 4, or 5 days.
  • the lymphodepleting treatment comprises administration of:
  • cyclophosphamide at 750 mg/m 2 /day (given for instance over 1 hour) for 3 days, such as from Day -4 to Day -2, with a maximum daily dose of 1.33 g, and
  • alemtuzumab at 12 mg/day (given for instance over 4 to 6 hours) for 4 days, such as Day -5 to Day -2.
  • Day -n or “D-n” represents “n” days before Day 0, where Day 0 is the day the immunotherapy treatment is initially planned to start (i.e. the day when the injection of the first dose of engineered CAR-T cells is planned). Day 0 can fluctuate by 1, 2, or 3 days if this would not be recommended to start the immunotherapy that exact day, for instance due to the patient having fever, etc. In that case, the injection of the first dose of CAR-T cells can be postponed by a couple of days, compared to the initially planned Day 0, till the patient is fit to start immunotherapy.
  • Day n or “Dn” represents “n” days after Day 0, where Day 0 is the day the immunotherapy treatment is initially planned to start as detailed above.
  • the lymphodepleting treatment starts between 2 and 8 days before the administration of the first dose of engineered T-cells as described herewith, such as between 2 and 5 days before, such as 2, 3, 4, or 5 days before.
  • the lymphodepleting treatment is completed before immunotherapy starts (i.e. before the administration of the first dose of engineered T-cells as described herewith), and the compounds like fludarabine, cyclophosphamide and alemtuzumab, are administered intravenously (IV).
  • the lymphodepletion treatment is followed by a cell-immunotherapy treatment using engineered immune cells, which are administered in 2 successive doses, referred herein as a 2-dose regimen.
  • the lymphodepleting treatment is administered prior to the administration of the first dose of CAR-T cells, and there is no further lymphodepleting treatment between the administration of the first dose and the administration of the second dose of CAR-T cells, concomitantly to the second dose of CAR-T cells, and/or for 28 days following the administration of the first dose of CAR-T cells.
  • a preconditioning lymphodepleting treatment is completed on or shortly before the administration of the first dose of CAR-T cells, such as within the 1, 2, 3, 4, or 5 days preceding the administration of the first dose, and there is no lymphodepleting treatment before at least 28 days after the administration of the first dose of CAR-T cells.
  • a further preconditioning lymphodepleting treatment can take place after 28 days, and up to months or years after the previous lymphodepleting treatment, as a preconditioning lymphodepleting treatment in a repeat of the method of treatment as described herewith, for a subject whose cancer relapsed or progressed, for instance, after having been treated according to the method described herewith.
  • the preconditioning lymphodepletion treatment takes place only before the administration of the first dose of CAR-T cells in a 2-dose regimen.
  • the methods of treating a subject having a cancer as disclosed herewith comprise administering successively, to the subject in need thereof, a first and second doses of engineered T-cells expressing a chimeric antigen receptor (CAR) (CAR-T cells), said CARs targeting specifically an antigen associated with the cancer.
  • CAR chimeric antigen receptor
  • the first dose of CAR-T cells is administered within about 3 and 8 days after the start of the pre-conditioning lymphodepleting treatment, such as 3, 4, 5, 6, 7, or 8 days after the start of the pre-conditioning lymphodepleting treatment, and/or between about 0 and 5 days after the completion of the pre-conditioning lymphodepleting treatment, such as on the day or 1, 2, 3, 4 or 5 days after the completion of the preconditioning lymphodepleting treatment.
  • the second dose of CAR-T cells is administered between about 10 and 20 days after the first dose of CAR-T cells, or between 10 and 17 days, such as after 10, 11, 12, 13, 14, 15, 16 or 17 days.
  • the second dose of CAR-T cells is administered 13, 14, or 15 days after the first dose of CAR-T cells.
  • the second dose of CAR-T cells is administered in the time-window when cytokine secretion measured in a patient’s sample (e.g. blood, biopsy) is between 10 and 1000 folds, or between 10 and 100 folds, higher than before the administration of the first dose of CAR-T cells, such as in the range of 10, 50, 100, 500, or 1000 folds higher.
  • cytokine secretion measured in a patient’s sample e.g. blood, biopsy
  • the second dose of CAR-T cells is administered in the time-window when cytokine secretion, e.g. IL-6, as measured in the patient’s blood, is between 10 and 1000 folds, or between 10 and 100 folds, higher than before the administration of the first dose of CAR-T cells, such as in the range of 10, 50, 100, 500, or 1000 folds higher.
  • cytokine secretion e.g. IL-6
  • the second dose of CAR-T cells is administered at least 3, 4, 5 days after the day when the number of CAR-T cells from the first dose reached a peak.
  • the first dose of CAR-T cells comprises between about 10 4 to about 10 8 CAR-T cells per kilogram body weight of the subject (cells/kg) and no more than 10 9 total CAR-T cells, or between about 10 5 to 10 9 total CAR-T cells
  • the second dose of CAR-T cells comprises between about 10 4 to about 10 8 CAR-T cells per kilogram body weight of the subject (cells/kg) and no more than 10 9 total CAR-T cells, or between about 10 5 to 10 9 total CAR-T cells.
  • the number of CAR-T cells in first dose is between about IxlO 5 and 1x10 7 cells/kg, between about 5 xlO 5 and 5 xlO 6 cells/kg, between about 6x10 5 and 3x10 6 cells/kg, between about 6x10 5 and 2x10 6 cells/kg
  • the number of CAR-T cells in the second dose is between about 1x10 5 and 1x10 7 cells/kg, between about 5 xlO 5 and 5 xlO 6 cells/kg, between about 6x10 5 and 3x10 6 cells/kg, between about 6x10 5 and 2x10 6 cells/kg.
  • the number of CAR-T cells in the first dose and the number of CAR- T cells in the second dose are identical.
  • the number of CAR-T cells in the first dose and the number of CAR- T cells in the second dose are different. In some cases, the number of CAR-T cells in the second dose is higher than the number of CAR-T cells in the first dose, such as between about 1.5 and 3 times higher, such as 1.5, 2, 2.5, or 3 times higher. In some cases, the number of CAR-T cells in the second dose is lower than the number of CAR-T cells in the first dose, such as between about 1.5 and 3 times lower, such as 1.5, 2, 2.5, or 3 times lower.
  • the number of CAR-T cells in the first dose is between about 5x10 5 and 5xl0 6 cells/kg, between about 5xlO 5 and 1x10 6 cells/kg, such as about 6 xlO 5 cells/kg, 6.2 xlO 5 cells/kg, 6.25 xlO 5 cells/kg, 6.5 xlO 5 cells/kg, 7 xlO 5 cells/kg
  • the number of CAR-T cells in the second dose is between about 1x10 6 and 5x10 6 cells/kg, between about 1.5xl0 6 and 4xl0 6 cells/kg, such as about 1.5xl0 6 cells/kg, 2xl0 6 cells/kg, 3xl0 6 cells/kg, 3.3xl0 6 cells/kg, 3.5xl0 6 cells/kg, 4xl0 6 cells/kg.
  • the antigen targeted by the CAR expressed by the CAR-T cells comprised in the first dose is identical to the antigen targeted by the CAR-T cells comprised in the second dose.
  • the antigen targeted by the CAR expressed by the CAR-T cells comprised in the first dose is different from the antigen targeted by the CAR-T cells comprised in the second dose.
  • the first and second doses of CAR-T cells express a CAR targeting the same antigen.
  • the first and second doses of CAR-T cells express a CAR targeting the same epitope of the same antigen.
  • the first and second doses of CAR-T cells express a CAR targeting different epitopes of the same antigen.
  • the first dose and/or second dose of CAR-T cells express a CD 123 CAR as described herewith.
  • the first dose and/or second dose of CAR-T cells express a CAR as described herewith.
  • the first dose and/or second dose of CAR-T cells comprise CAR-T cells which have the genetic modifications described herewith.
  • the first dose and/or the second dose of CAR-T cells comprise CAR- T cells which have been genetically modified to suppress or repress expression of at least one component of a T-Cell Receptor (TCR) at the surface of said CAR-T cells.
  • the first dose and/or the second dose of CAR-T cells comprise CAR- T cells which have been genetically modified to suppress or repress expression of at least one gene encoding a MHC-I protein, such as 02m and HLA.
  • the first dose and/or the second dose of CAR-T cells comprise CAR- T cells which have been genetically modified to suppress or repress expression of a gene encoding an immune checkpoint protein and/or a receptor thereof.
  • the first dose and/or the second dose of CAR-T cells comprise CAR- T cells which have been genetically modified to confer resistance to at least one immune suppressive or chemotherapy drug
  • the first dose and/or the second dose of CAR-T cells comprise CAR- T cells which have been genetically modified to be CD52 negative.
  • the first dose and/or the second dose of CAR-T cells comprise CAR- T cells which have been genetically modified to be at least CD52 and TCR negative
  • the first dose and/or the second dose of CAR-T cells comprise CAR- T cells which have been genetically modified to be at least one of CD52 negative, TCR negative, B2M negative, and PDCD1 negative.
  • the first dose and/or the second dose of CAR-T cells comprise CAR- T cells which have been genetically modified to comprise a suicide gene.
  • the first dose and/or the second dose of CAR-T cells comprise, integrated in their genome, an exogenous nucleic acid sequence encoding a suicide domain such as QBEN10 having an amino acid sequence comprising SEQ ID NO: 23.
  • one or more additional doses of CAR-T cells can be administered after the second dose of CAR-T cells as described herewith, in the timewindow comprised between the day following the administration of the second dose and 28 days following the administration of the first dose, e.g. between about D14 and D28.
  • the administration of these one or more additional doses of CAR-T cells can occur without prior lymphodepleting treatment (except for the one that occurred before the administration of the first dose).
  • these one or more additional doses of CAR-T cells are characterized by similar features in respect to the concentration of CAR-T cells, the phenotypic and genetic characteristics of the CAR-T cells, as described herewith for the first and second doses.
  • the methods described herewith can also comprise the administration of a drug to prevent or treat Cytokine Release Syndrom (CRS), such as an anti-IL6 therapy such as anti-IL6 antibody or an anti-IL6R antibody.
  • CRS Cytokine Release Syndrom
  • the drug for preventing CRS can be administered before, at the same time, or after administration of the CAR-T cells.
  • the administration of the drug for preventing CRS is administered before the CAR-T cells, and is, optionally, completed at least 1 hour before the administration of the CAR-T cells.
  • the methods described herewith comprise administering an anti-IL6 or anti-IL6R antibody on the same day as the first dose of CAR-T cells and/or on the same day as the second dose of CAR-T cells.
  • the drug for preventing CRS such as an anti-IL6 antibody or anti- IL6R antibody, is administered the same day as the CAR-T cells.
  • Tocilizumab is a humanized anti-IL-6R monoclonal antibody recommended by the ASTCT (Lee etal. (2019) Biol Blood Marrow Transplant. 25, 625-638) and has marketing authorization for the treatment of CRS
  • the methods described herewith comprise administering tocilizumab on the same day as the first dose of CAR-T cells and/or on the same day as the second dose of CAR-T cells.
  • Tocilizumab is administered intravenously at a dose comprised between 5 and 100 mg/kg, between 10 and 50 mg/kg, or at about 7, 8, 9, or 10 mg/kg, optionally at a maximum total dose of 800 mg.
  • the administration of tocilizumab is completed at least 1 hour before the administration of the first and second doses of CAR-T cells.
  • the methods described herewith is followed by a bone marrow transplant in the patient. In some cases, the methods described herewith are carried out in view of a bone marrow transplant in the patient having a cancer.
  • compositions described herewith could be used for treating a patient having any cancer including solid tumors and haematological cancers.
  • said cancer is a pre-malignant or malignant cancer condition characterized by an overabundance of CD 123 -expressing cells.
  • said cancer is a haematological cancer, such as a leukemia or a malignant lymphoproliferative disorder.
  • said leukemia is selected from the group consisting of acute myelogenous leukemia (AML), chronic myelogenous leukemia, melodysplastic syndrome, acute lymphoid leukemia (ALL), chronic lymphoid leukemia, and myelodysplastic syndrome.
  • AML acute myelogenous leukemia
  • ALL acute lymphoid leukemia
  • myelodysplastic syndrome a group consisting of acute myelogenous leukemia (AML), chronic myelogenous leukemia, melodysplastic syndrome, acute lymphoid leukemia (ALL), chronic lymphoid leukemia, and myelodysplastic syndrome.
  • said leukemia is acute myelogenous leukemia (AML).
  • said hematological cancer is a malignant lymphoproliferative disorder.
  • said malignant lymphoproliferative disorder is a lymphoma.
  • said lymphoma is selected from the group consisting of multiple myeloma, non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell).
  • the methods and compositions described herewith are for use in the treatment of cancers selected from the group consisting of acute myeloid leukemia (AML), Acute lymphocytic leukemia (ALL), and Non-Hodgkin Lymphoma (NHL).
  • AML acute myeloid leukemia
  • ALL Acute lymphocytic leukemia
  • NHL Non-Hodgkin Lymphoma
  • AML patients with complex cytogenetic abnormalities and/or TP53 mutations i.e. classified into the ELN Adverse genetic risk group (Dbhner etal., 2017, Blood. 129, 424- 447) specifically fall into the category of urgent unmet medical need, as these patients have especially dismal outcomes with all existing treatment modalities, including allogeneic transplantation.
  • the methods and compositions for use described herewith could be used for treating patients with adverse genetic risk AML or as pre-treatment for patients with adverse genetic risk AML in view of obtaining more successful bone marrow transplant.
  • Adverse genetic risk is defined as per ELN guidelines (Dbhner et al., 2017, Blood. 129, 424-447) by any of the following genetic signatures: a. t(6;9)(p23;q34.1); DEK-NUP214; or b . t(v; 11 q23.3 ) ; KMT2 A rearranged; or c. t(9;22)(q34.1;ql l.2); BCR-ABL1 ; or d. inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVIl); or e.
  • Monosomal karyotype comprising presence of one single monosomy (excluding loss of X or Y) in association with at least one additional monosomy or structural chromosome abnormality (excluding core-binding factor AML); or h. Wild-type NPM1 and FLT3-ITD high or i. Mutated RUNX1 (except if co-occur with favorable-risk AML subtypes) or j. Mutated ASXL1 (except if co-occur with favorable-risk AML subtypes) or k. Mutated TP53.
  • compositions described herewith are for use in the treatment of AML in a patient who has at least one genetic marker selected from:
  • - Complex karyotype Three or more unrelated chromosome abnormalities in the absence of one of the World Health Organization-designated recurring translocations or inversions, i.e., t(8;21), inv(16) or t(16;16), t(9;l l), t(v;l l)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCR-ABL1; or
  • Monosomal karyotype presenting one single monosomy (excluding loss of X or Y) in association with at least one additional monosomy or structural chromosome abnormality (excluding core-binding factor AML); or
  • the methods and compositions described herewith are for use in the treatment of AML in a patient who has at least one genetic marker that is Mutated TP53.
  • compositions comprising engineered T- cells expressing a CAR or recombinant TCR, useful in the methods described herewith, and a pharmaceutical acceptable excipient.
  • compositions comprising engineered CAR-T cells useful in the methods described herewith, and a pharmaceutical acceptable excipient.
  • compositions comprising a population of T-cells comprising the engineered CAR-T cells useful in the methods described herewith, and a pharmaceutical acceptable excipient.
  • compositions comprising a first or second dose of engineered T-cells expressing a CAR (CAR-T cells), said CAR targeting specifically an antigen associated with a cancer, for use in the treatment of a subject having said cancer, according to the methods of treatment described herewith.
  • CAR-T cells engineered T-cells expressing a CAR
  • said CAR targeting specifically an antigen associated with a cancer for use in the treatment of a subject having said cancer, according to the methods of treatment described herewith.
  • a pharmaceutical composition comprising a first or second dose of engineered T-cells expressing a CAR (CAR-T cells), said CAR targeting specifically an antigen associated with a cancer, for use in the treatment of a subject having said cancer; - wherein said treatment comprises administering the first and second doses of said CAR-T cells successively;
  • the subject has been preconditioned with a lymphodepleting treatment to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood;
  • no lymphodepleting treatment is administered between the first and second doses of CAR-T cells, concomitantly to the second dose of CAR-T cells, and/or on any one of the at least 20 days following the administration of the first dose of CAR- T cells;
  • engineered CAR-T cells are CD 52 negative.
  • a pharmaceutical composition comprising one dose of CAR-T cells, said CAR targeting specifically an antigen associated with a cancer, for use in the treatment of a subject having said cancer; wherein said treatment comprises administering a first dose of CAR-T cells and a second dose of CAR-T cells successively; wherein the second dose of CAR-T cells is administered between 10 and 17 days after the first dose of CAR-T cells; wherein, prior to the administration of the first dose of CAR-T cells, the subject has been preconditioned with a lymphodepleting treatment to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood; wherein no lymphodepleting treatment is administered between the first and second doses of CAR-T cells, concomitantly to the second dose of CAR-T cells, and/or on any one of the at least 20 days following the
  • Also disclosed herewith is a combination of a pharmaceutical composition comprising a first dose of engineered T-cells expressing a CAR (CAR-T cells) and a pharmaceutical composition comprising a second dose of engineered T-cells expressing a CAR (CAR-T cells), said CARs targeting specifically an antigen associated with a cancer, for use in the treatment of a subject having said cancer;
  • said treatment comprises administering the first and second doses of said CAR-T cells successively;
  • the subject has been preconditioned with a lymphodepleting treatment to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood;
  • no lymphodepleting treatment is administered between the first and second doses of CAR-T cells, concomitantly to the second dose of CAR-T cells, and/or on any one of the at least 20 days following the administration of the first dose of CAR- T cells;
  • engineered CAR-T cells are CD 52 negative.
  • a pharmaceutical composition for use in the treatment of a cancer as mentioned above wherein said T cells and CAR-T cells are as described in the present document, said lymphodepleting treatment is as described in the present document, said first and second doses of CAR-T cells are as described in the present document, and said cancer is as described in the present document.
  • a combination of pharmaceutical compositions for use in the treatment of a cancer as mentioned above wherein said T cells and CAR-T cells are as described in the present document, said lymphodepleting treatment is as described in the present document, said first and second doses of CAR-T cells are as described in the present document, and said cancer is as described in the present document.
  • compositions comprising a first or a second dose of engineered T-cells expressing a CAR specific for CD 123 (CD 123 CAR-T cells), for use in the treatment of a subject having a cancer characterized by CD 123- expressing cells;
  • said treatment comprises administering successively said first and second doses of said CD123CAR-T cells;
  • CD123CAR-T cells wherein the second dose of CD123CAR-T cells is administered between 10 and 17 days after the first dose of CAR-T cells, such as after 10, 11, 12, 13, 14, 15, 16 or 17 days;
  • the subject has been preconditioned with a lymphodepleting treatment comprising fludarabine, cyclophosphamide and alemtuzumab to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood;
  • a lymphodepleting treatment comprising fludarabine, cyclophosphamide and alemtuzumab
  • no lymphodepleting treatment is administered between the first and second doses of CD123CAR-T cells, concomitantly to the second dose of CD123CAR-T cells, and/or on any one of the at least 20 days following the administration of the first dose of CD123CAR-T cells;
  • CD 123 CAR-T cells comprises between about 10 4 to about 10 8 CD123CAR-T cells per kilogram body weight of the subject (cells/kg) and no more than 10 9 total CD 123 CAR-T cells, or between about 10 5 to 10 9 total CD123CAR-T cells;
  • CD123CAR-T cells are CD52 negative, and, optionally, TCR negative.
  • Also provided herewith is a combination of a pharmaceutical composition comprising a first dose of CD123CAR-T cells and a pharmaceutical composition comprising a second dose of CD123CAR-T cells, for use in the treatment of a subject having a cancer characterized by CD 123 -expressing cells;
  • said treatment comprises administering successively said first and second doses of said CD123CAR-T cells;
  • CD123CAR-T cells wherein the second dose of CD123CAR-T cells is administered between 10 and 17 days after the first dose of CD123CAR-T cells, such as after 10, 11, 12, 13, 14, 15, 16, or 17 days;
  • the subject has been preconditioned with a lymphodepleting treatment comprising fludarabine, cyclophosphamide and alemtuzumab to eliminate, at least partially, the subject’s own immune cells to have, from at least the day of the administration of the first dose of CAR-T cells and for at least the 20 following days, less than 500 absolute lymphocyte counts per pl of subject’s whole blood;
  • a lymphodepleting treatment comprising fludarabine, cyclophosphamide and alemtuzumab
  • no lymphodepleting treatment is administered between the first and second doses of CD123CAR-T cells, concomitantly to the second dose of CD123CAR-T cells, and/or on any one of the at least 20 days following the administration of the first dose of CD123CAR-T cells;
  • CD 123 CAR-T cells comprises between about 10 4 to about 10 8 CD123CAR-T cells per kilogram body weight of the subject (cells/kg) and no more than 10 9 total CD 123 CAR-T cells, or between about 10 5 to 10 9 total CD123CAR-T cells;
  • CD123CAR-T cells are CD52 negative, and, optionally, TCR negative.
  • said CD123CAR-T cells are CD52 negative and TCR negative.
  • said CD123CAR-T cells have, integrated in their genome, an exogenous sequence encoding a suicide domain having an amino acid sequence comprising SEQ ID NO: 23.
  • said lymphodepleting treatment comprises administration of:
  • - fludarabine at between about 1 and 100 mg/m 2 /day, between about 10 and 75 mg/m 2 /day, between about 15 and 50 mg/m 2 /day, between about 20 and 40 mg/m 2 /day, or about 25, 30 or 40 mg/m 2 /day, for 1, 2, 3, 4, or 5 days;
  • - cyclophosphamide at between about 50 and 10 000 mg/m2/day, between 50 and 5 000 mg/m 2 /day, between 50 and 1000 mg/m 2 /day, between 100 and 1000 mg/m 2 /day, between 500 and 1000 mg/m 2 /day, between 600 and 800 mg/m 2 /day, or about 600, 650, 700, 750 or 800 mg/m 2 /day, for 1, 2, 3, or 4 days;
  • - alemtuzumab at between about 5 and 50 mg/day, between 10 and 40 mg/day, between 10 and 20 mg/day, or at 10, 11, 12, 13, 14, or 15 mg/day, for 1, 2, 3, 4, or 5 days.
  • said second dose of CD123CAR-T cells is administered 13, 14, or 15 days after the first dose of CD123CAR-T cells.
  • the first dose and/or the second dose of CD123CAR-T cells comprises between about 10 5 to about 10 7 CD123CAR-T cells per kilogram body weight of the subject (cells/kg), such as from about 6.0 to 6.5 xlO 5 , from about 1.0 to 1.5 xlO 6 , from about 3.0 to 3.5 xlO 6 , or from about 5.0 to 5.5 xlO 6 CD123CAR- T cells/kg, and no more than 5.10 8 total CD123CAR-T cells.
  • said first dose and/or second dose of CAR-T cells comprises CAR-T cells expressing a CAR targeting CD 123 having a polypeptide structure comprising an extra cellular ligand binding-domain comprising a heavy chain variable region (VH) and a light chain variable region (VL) from a monoclonal anti-CD123 antibody, a CD8a hinge, a CD8a transmembrane domain, and a cytoplasmic domain including a CD3 signaling domain and a co-stimulatory domain from 4- IBB, wherein said VH comprises the CDR sequences of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15 and said VL comprises the CDR sequences of SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18.
  • said VH has at least 80% identity with SEQ ID NO: 11 and comprises the CDRs of amino acid sequences SEQ ID NO: 13 to SEQ ID NO: 15, and said VL has at least 80% identity with SEQ ID NO: 12 and comprises the CDRs of amino acid sequences SEQ ID NO: 16 to SEQ ID NO: 18.
  • said VH comprises the amino acid sequence of SEQ ID NO: 11 and said VL comprises the amino acid sequence of SEQ ID NO: 12.
  • said CAR targeting CD 123 comprises an amino acid sequence having at least 80% sequence identity with SEQ ID NO: 19, and comprises the CDRs of amino acid sequences SEQ ID NO: 13 to 18.
  • said CAR targeting CD 123 comprises the amino acid sequence of SEQ ID NO: 19.
  • said CD 123 CAR-T cells have, integrated in their genome, an exogenous sequence encoding a suicide domain having an amino acid sequence comprising SEQ ID NO: 23.
  • said cancer is a pre-malignant or malignant cancer condition characterized by an overabundance of CD 123 -expressing cells. In some cases of said pharmaceutical composition for use or of said combination of pharmaceutical compositions for use, said cancer is a haematological cancer.
  • said cancer is an haematological cancer that is a leukemia or a malignant lymphoproliferative disorder.
  • said cancer is a leukemia selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, melodysplastic syndrome, acute lymphoid leukemia, chronic lymphoid leukemia, and myelodysplastic syndrome.
  • said cancer is a leukemia that is acute myelogenous leukemia (AML).
  • AML acute myelogenous leukemia
  • said cancer is an hematological cancer that is a malignant lymphoproliferative disorder.
  • said cancer is a malignant lymphoproliferative disorder that is a lymphoma.
  • said cancer is a lymphoma selected from the group consisting of multiple myeloma, non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell).
  • T-cells expressing a CAR Although the methods and compositions of the invention are mainly described with T-cells expressing a CAR, they also apply to T-cells expressing a recombinant TCR, since in both cases the CAR and/or the TCR binds specifically to the antigen associated with the cancer from which the patient is affected.
  • the CD 123 CAR construct selected for use in Universal Chimeric Antigen Receptor T-cells targeting CD123 combines a scFv specific for CD123, the CD8 alpha hinge region and transmembrane domain, and a cytoplasmic tail composed of 4-1BB co -stimulatory and CD3 zeta signaling domains.
  • the lentiviral vector cassette that drives expression of the CD 123 CAR was designed to coexpress RQR8 (through a 2A peptide linker).
  • RQR8 is a 136 amino acid artificial cell surface protein combining target epitopes from both human CD34 (to detect RQR8 using the QbendlO antibody) and human CD20 antigens.
  • the expression of RQR8 on UCART123 cells permits targeted destruction of RQR8+ CD123 CAR+ T -cells through administration of rituximab.
  • UCART123 was additionally engineered to be TCRo.p negative through inactivation of the T-cell receptor alpha constant (TRAC) gene, using the Transcription Activator-Like Effector Nuclease (TALEN®) technology (see Table 2).
  • TALENs® are artificially engineered nucleases that are capable of generating site-specific deoxyribonucleic acid (DNA) double-strand breaks at a desired target site leading to inactivation of the targeted gene.
  • TRAC graft-versus-host disease
  • UCART123 cells are also engineered with a second TALEN® targeting the CD52 gene (see Table 3), in order to produce a mixture of CD52+ and CD52- cells.
  • CD52- cells will be resistant to cell depletion by anti-CD52 therapies such as the monoclonal antibody alemtuzumab. This allows therefore the potential use of this monoclonal antibody in the lymphodepleting regimen prior to treatment withUCART123.
  • the UCART123 product comprises allogeneic engineered CAR-T cells which co-express a CAR targeting CD 123 and RQR8 and are knocked-out for TRAC and CD52 genes.
  • the CAR expressed by the UCART123 comprises a VH of SEQ ID NO: 11, a VL of SEQ ID NO: 12, a CD8 alpha hinge of SEQ ID NO: 4, a CD8 alpha transmembrane of SEQ ID NO: 6, a CD3zeta stimulatory domain of SEQ ID NO: 9, and a 4-1 BB costimulatory domain of SEQ ID NO: 8.
  • RQR8 comprises the amino acid sequence of SEQ ID NO: 23.
  • This example briefly describes the schedule and conditions, as initially planned, of the on-going clinical trial of UCART123 in AML.
  • the study comprises a dose escalation phase with UCART123 in patients with relapsed or refractory (R/R) AML, and a dose-expansion phase in which additional patients with R/R AML will be enrolled to further evaluate the safety and preliminary efficacy of UCART123 at the dose/schedule and with the corresponding lymphodepletion regimen selected for further study.
  • the dose escalation with UCART123 explores the doses of UCART123 ranging from 1.25xl0 5 CD123CAR+ T-cells/kg to 5.05xl0 6 CD123CAR+ T-cells/kg (including DL1 of 2.5xl0 5 , DL2 of 6.25xl0 5 , and DL3 of 3.30xl0 6 CD123CAR+ T-cells/kg). Intermediate dose levels (e.g. DL2i of 1.5 xlO 6 CD123CAR+ T-cells/kg) could also be tested. Table 4 summarizes the dose-levels tested.
  • the lymphodepleting regimen can be modified (either in composition or in doses) and adapted during the study upon safety, biological, and/or clinical activity observations.
  • a lymphodepleting regimen consisting of either fludarabine and cyclophosphamide administered alone (Arm FC) or in combination with alemtuzumab (Arm FCA).
  • lymphodepleting regimen consisting of fludarabine and cyclophosphamide administered in combination with alemtuzumab (Arm FCA).
  • Arms FC and FCA already started and progressed from DL1 through DL2 and DL2i, till up to, at least DL3.
  • a two-dose regimen is added to the FCA Arm in the dose escalation to evaluate the safety and preliminary anti-leukemia activity of 2 infusions of UCART123 where the first infusion is preceded by a lymphodepletion, while the second infusion is not.
  • Figure 1 gives a schematic representation of a single-dose regimen (A) and a 2- dose regimen according to the methods described herewith (B).
  • A a single-dose regimen
  • B a 2- dose regimen according to the methods described herewith
  • one dose of CAR-T cells is administered after a preconditioning lymphodepleting treatment.
  • This single-regimen may be repeated (i.e. administering another dose of CAR-T cells after another preconditioning lymphodepleting treatment) on a case-by-case basis after having completed the DLT observation period (i.e. after at least D28).
  • CAR T-cells are infused on DO and a second infusion of the equivalent, higher, or lower dose of CAR T-cells occurs around D14 with no additional lymphodepletion.
  • the DLT observation period is 42 days starting from DO and can be extended to 8 weeks for patients with clinically significant cytopenias and/or bone marrow aplasia.
  • the lymphodepleting regimen preceding UCART123 administration will consist of fludarabine and cyclophosphamide administered alone (Arm FC) or in combination with alemtuzumab (Arm FCA).
  • lymphodepleting regimen will start as early as possible after enrollment. Patients must be hospitalized for lymphodepletion (beginning on Day -5).
  • Arm FC comprises administration of fludarabine and cyclophosphamide (FC) as follows: a) fludarabine 30 mg/m 2 /day IV given over 15 to 30 minutes for 4 days from Day -5 to Day -2 with a maximum daily dose of 60 mg b) cyclophosphamide 750 mg/m 2 /day IV given over 1 hour for 3 days from Day -4 to Day -2 with a maximum daily dose of 1.33 g
  • Arm FCA comprises administration of fludarabine, cyclophosphamide and alemtuzumab (FCA) as follows: a) fludarabine 30 mg/m 2 /day IV given over 15 to 30 minutes for 4 days (from Day -5 to Day -2) with a maximum daily dose of 60 mg b) cyclophosphamide 750 mg/m 2 /day IV given over 1 hour for 3 days (from Day -4 to Day -2) with a maximum daily dose of 1.33 g c) alemtuzumab 12 mg/day IV over 4 to 6 hours for 4 days (Day -5 to Day -2)
  • the doses and schedules of fludarabine, cyclophosphamide and alemtuzumab used in the lymphodepletion regimen may be changed during the study based on the ongoing review of the safety, activity, and translational data.
  • the total dose of alemtuzumab used in FCA regimen may be increased to a total of 60 mg if lymphodepletion observed is not sufficient to promote UCART123 expansion, proliferation, and persistence.
  • lymphodepletion will take place from Day -5 to Day -2 during the week preceding UCART123 infusion at Day 0. Medical or other events may delay UCART123 infusion up to 2 days at the investigator’s discretion, with an appropriate documented rationale.
  • the administration date of the initial UCART123 infusion is defined as Day 0 (DO). On Day 0, patients will receive an intravenous (IV) dose of UCARTT23 calculated based on the weight recorded at DO, as slow infusion.
  • IV intravenous
  • UCART123 product is administered at one of the doses mentioned in Table 4.
  • administration of a second dose of UCART123 may be considered on a case-by-case basis.
  • Administration of a second dose could be considered, for instance, if the patient has either stable disease or some level of reduction in bone marrow blasts and no safety complications related to the administration of the first dose of UCART123.
  • the patient may be retreated at the same, lower, or higher dose of UCART123 than previously received.
  • the administration of this second dose of UCART123 will require a second period of lymphodepletion prior to administration of the second dose of UCART123, where this second lymphodepletion regimen may be the same or different than the one the patient previously received (i.e. FC, FCA or changes in dose and schedule of the agents).
  • a second dose of UCART123 will be preceded or concomitant to a lymphodepletion treatment
  • this will constitute a repetition of classical single dose regimen preceded by a lymphodepleting, i.e. repeating the combination of a lymphodepletion treatment and a CAR-T infusion, after having observed that the first single dose regimen treatment was not sufficient to obtain a partial or complete response in the patient.
  • the first administration of UCART123 at Day 0 is preceded by lymphodepletion as described above (FCA), followed by a second administration of UCART123 between Day 14 and 17 without carrying out another lymphodepletion treatment between DO and D28.
  • FCA lymphodepletion as described above
  • the first and second infusions of UCART123 can be combined with the administration of Tocilizumab with or without concomitant corticosteroids as a prophylactic treatment of CAR-T cell-associated cytokine release syndrome.
  • Tocilizumab (8 mg/kg and maximum total dose 800 mg) will be administered on Day 0 intravenously over 1 hour and should be completed at least 1 hour before UCART123 infusion.
  • Tocilizumab is a humanized anti-IL-6R monoclonal antibody recommended by the ASTCT (Lee et al. (2019) Biol Blood Marrow Transplant. 25, 625-638) and has marketing authorization for the treatment of CRS.
  • UCART123 product will be administered at one of the doses mentioned in Table 4.
  • UCART123 dose level 2 (6.25x 10 5 cells/kg) is the first dose planned based on the safety data generated to date.
  • the day the patient receives the initial infusion of CAR-T cells defines Day 0.
  • the second infusion of CAR-T cells is planned to be administered between Day 14 and 17, provided the patient meets the criteria for giving the second dose as outlined below.
  • the eligibility criteria for second UCART123 administration are as follows:
  • Adequate organ function including renal and hepatic function based on the last assessment performed within the Screening Period, defined as: i) Creatinine clearance >60 mL/min (assessed as glomerular filtration rate using the Cockcroft & Gault formula or MDRD); ii) Alanine aminotransferase and aspartate aminotransferase ⁇ 3 x upper limit of normal (ULN); iii) Total bilirubin ⁇ 2 x ULN (except for patients with a history of Gilbert’s Syndrome confirmed by UGT1A1 mutation); iv) Left ventricular ejection fraction (LVEF) >50% as assessed by echocardiography or Multi Gated Acquisition Scan (MUGA); and v) Must have a minimum level of pulmonary reserve defined as Grade ⁇ 2 dyspnea and pulse oxygenation >92% on room air.
  • Creatinine clearance >60 mL/min assessed as glomerular filtration rate using the Cockcroft & Gault formula or MDRD
  • Safety endpoints include Incidence, nature, and severity of adverse events and serious adverse events (SAEs) throughout the study (CTCAE v5.0; Lee et al. (Biol Blood Marrow Transplant. (2019) 25, 625-638) for CRS; Cairo and Bishop (Br. J. Haematol. (2004) 127, 3-11) for TLS, New consensus criteria 2016 (Harris et al (J. Am. Soc. Blood Marrow Transplant. (2016) 22, 4-10) for GvHD.
  • Efficacy endpoints include:
  • Exploratory endpoints include:
  • CD 123 CAR+ T-cells including CD4+ and CD8+ subsets measured by multiparameter flow cytometry in blood and bone marrow;
  • CD 123 CAR transcripts by digital polymerase chain reaction (ddPCR) or other methods in blood and bone marrow;
  • ddPCR digital polymerase chain reaction
  • HAMA human anti-mouse antibody
  • HSCs CD34+ cells
  • Comparison of Figures 2A and 3A shows that absolute lymphocyte counts measured by a complete cell count and differential is about 0 for 10 days after FC, while it is about 0 for about at least 20 days after FCA pre-conditioning lymphodepleting regimen.
  • addition of alemtuzumab to a lymphodepleting regimen comprising fludarabine and cyclophosphamide prolongs the depletion of patient’s immune cells by at least 10 more days.
  • UCART123 expansion measured by qPCR from the patient’s whole blood sample, started after between about 5-10 days after the administration of UCART123 and reached a plateau at about 10-12 days. Depending on the patient, the peak of UCART123 was maintained for about 10 more days or dropped quickly in a couple of days.
  • IL-2 secretion peaked 1-2 days after 1 st dose UCART-123 infusion.
  • IL-2 constitutes an early biomarker for UCART123 cell proliferation.
  • IL-6, IFN-gamma and TNF-alpha secretions were correlated with UCART123 cell expansion window.
  • cytokines secretion was in the same range as patients with Grade 1 CRS.
  • the results of this example shows that the first dose of CAR-Ts generates a pro- inflammatory environment that could enhance the activity of a second dose of CAR-Ts.
  • Anti-leukemic activity of UCART123 as measured by flow cytometry in the sample of a patient pretreated with either FC or FCA and then treated with a first dose of UCART123 (DL2) is represented in Figures 2C (FC) and 3C (FCA), respectively.
  • FCA, DL2 Achieved greater than 90% BMblast reduction (60% to 5%) at D28 (Stable Disease).
  • Results of Examples 4 to 6 show that UCART123 expansion correlated with reduction in tumor burden at DL2 (6.25 x 10 5 cells/kg) but, at this dose, UCART123 cell function was not sufficient for sustained anti-leukemic activity in all patients.
  • the leukemia debulking effect of the first dose of UCART123 could help restore bone marrow stromal function to support homeostasis of the immune system and increase local availability of cytokines that are necessary for C AR-T cells survival and expansion.
  • a second dose of UCART123, administered between DIO to D17 could benefit from a favorable micro-environment and complete the reduction of the tumor and, thus, treat the patient’s cancer more efficiently.
  • AMELI-01 is a Phase 1 open-label dose-escalation trial evaluating the safety, tolerability, expansion and persistence of UCART123 given at escalating dose levels after lymphodepletion (LD) with either fludarabine and cyclophosphamide (FC) or FC with alemtuzumab (FCA) in patients with r/r AML.
  • LD lymphodepletion
  • FC fludarabine and cyclophosphamide
  • FCA alemtuzumab
  • Alemtuzumab was added to the LD regimen to sustain host T-cell and Natural Killer (NK) cell depletion and to promote UCART123 - cell expansion and persistence.
  • Preliminary data from patients who received UCART123 at one of the following dose levels: dose level 1 (DL1) 2.5xl0 5 cells/kg; dose level 2 (DL2) 6.25xl0 5 cells/kg; intermediate dose level 2 (DL2i) 1.5xl0 6 cells/kg; or dose level 3 (DL3) 3.30xl0 6 cells/kg after lymphodepletion with FC or FCA are as follows:
  • Cytokine release syndrome occurred in 8 patients in the FC arm and 9 patients in the FCA arm.
  • 1 patient experienced Grade 3 immune effector cell- associated neurotoxicity syndrome (ICANS) and 2 patients experienced Grade 4 protocol- defined dose limiting toxicities (DLTs).
  • DLTs protocol- defined dose limiting toxicities
  • 2 patients experienced Grade 5 DLTs secondary to CRS.
  • the accumulated translational data to date demonstrates adequate lymphodepletion during the 28-day DLT period after one cycle of the current lymphodepletion regimen. Further, the current regimen and interval of lymphopenia has shown to correlate with UCART123 expansion and signs of clinical activity.
  • a second dose of UCART123 cells given during the Day 10 -Day 17 window could allow for a second period of UCART123 expansion with the intent of improving the clinical activity without adding unnecessary toxicity of an additional UCART123 infusion as the overall disease burden will be reduced at the time of the second infusion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Le présent document concerne des méthodes d'immunothérapie comprenant l'administration de cellules CAR-T à un sujet en ayant besoin, en particulier un régime à 2 doses de thérapie CAR-T, et des matériaux et des compositions pour mettre en œuvre de telles méthodes.
PCT/EP2023/084892 2022-12-09 2023-12-08 Régime à deux doses en immunothérapie WO2024121385A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263386697P 2022-12-09 2022-12-09
US63/386,697 2022-12-09
DKPA202370033 2023-01-20
DKPA202370033 2023-01-20

Publications (1)

Publication Number Publication Date
WO2024121385A1 true WO2024121385A1 (fr) 2024-06-13

Family

ID=89158041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/084892 WO2024121385A1 (fr) 2022-12-09 2023-12-08 Régime à deux doses en immunothérapie

Country Status (1)

Country Link
WO (1) WO2024121385A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2013176915A1 (fr) 2012-05-25 2013-11-28 Roman Galetto Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
WO2014039523A1 (fr) 2012-09-04 2014-03-13 Cellectis Récepteur d'antigène chimérique multicaténaire et utilisations de celui-ci
WO2014184744A1 (fr) 2013-05-13 2014-11-20 Cellectis Procédés de production, par génie génétique, d'un lymphocyte t hautement actif à vocation immunothérapeutique
WO2015075195A1 (fr) 2013-11-22 2015-05-28 Cellectis Procédé de modification de lymphocytes t résistant aux médicaments de chimiothérapie pour une immunothérapie
WO2015136001A1 (fr) 2014-03-11 2015-09-17 Cellectis Procédé d'obtention de lymphocytes t compatibles avec la transplantation allogénique
WO2016064929A1 (fr) * 2014-10-20 2016-04-28 Juno Therapeutics, Inc. Procédés et compositions pour dosage en thérapie cellulaire adoptive
WO2016120216A1 (fr) 2015-01-26 2016-08-04 Cellectis Systèmes de récepteurs d'antigènes chimériques dirigés par des mab pour trier/appauvrir les cellules immunitaires génétiquement modifiées
WO2020007593A1 (fr) 2018-07-02 2020-01-09 Cellectis Cellules exprimant des récepteurs d'antigènes chimériques (car) et traitement combiné pour l'immunothérapie de patients atteints de lma récidivante ou réfractaire avec un risque génétique indésirable
US10870864B2 (en) 2013-05-29 2020-12-22 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683195B1 (fr) 1986-01-30 1990-11-27 Cetus Corp
WO2013176915A1 (fr) 2012-05-25 2013-11-28 Roman Galetto Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
WO2014039523A1 (fr) 2012-09-04 2014-03-13 Cellectis Récepteur d'antigène chimérique multicaténaire et utilisations de celui-ci
WO2014184744A1 (fr) 2013-05-13 2014-11-20 Cellectis Procédés de production, par génie génétique, d'un lymphocyte t hautement actif à vocation immunothérapeutique
US10870864B2 (en) 2013-05-29 2020-12-22 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
WO2015075195A1 (fr) 2013-11-22 2015-05-28 Cellectis Procédé de modification de lymphocytes t résistant aux médicaments de chimiothérapie pour une immunothérapie
WO2015136001A1 (fr) 2014-03-11 2015-09-17 Cellectis Procédé d'obtention de lymphocytes t compatibles avec la transplantation allogénique
WO2016064929A1 (fr) * 2014-10-20 2016-04-28 Juno Therapeutics, Inc. Procédés et compositions pour dosage en thérapie cellulaire adoptive
WO2016120216A1 (fr) 2015-01-26 2016-08-04 Cellectis Systèmes de récepteurs d'antigènes chimériques dirigés par des mab pour trier/appauvrir les cellules immunitaires génétiquement modifiées
WO2020007593A1 (fr) 2018-07-02 2020-01-09 Cellectis Cellules exprimant des récepteurs d'antigènes chimériques (car) et traitement combiné pour l'immunothérapie de patients atteints de lma récidivante ou réfractaire avec un risque génétique indésirable

Non-Patent Citations (45)

* Cited by examiner, † Cited by third party
Title
"Handbook Of Experimental Immunology", 1986, COLD SPRING HARBOR LABORATORY PRESS
"The Encyclopedia of Molecular Biology", 1994, BLACKWELL PUBLISHERS
ABRAMSON J S ET AL: "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study", THE LANCET, vol. 396, no. 10254, 19 September 2020 (2020-09-19), pages 839 - 852, XP093065718, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(20)31366-0 *
ABRAMSON J S ET AL: "Supplementary Appendix", THE LANCET, vol. 396, no. 10254, 19 September 2020 (2020-09-19), pages 1 - 36, XP093065722, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(20)31366-0 *
ASHWELLKLUSNER, ANNU. REV. IMMUNOL., vol. 8, 1990, pages 139 - 67
B. PERBAL, A PRACTICAL GUIDE TO MOLECULAR CLONING, 1984
CAIROBISHOP, BR. J. HAEMATOL., vol. 127, 2004, pages 3 - 11
CHUNG ET AL., CELL STEM CELL, vol. 2, no. 2, 2008, pages 113 - 117
COFFIN, J. M. ET AL.: "Fundamental Virology", 1996, LIPPINCOTT-RAVEN PUBLISHERS, article "Retroviridae: The viruses and their replication"
COSTELLO C L ET AL: "Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies", BLOOD, vol. 136, no. Suppl. 1, 29, 5 November 2020 (2020-11-05), 62nd American Society of Hematology Annual Meeting; San Diego, CA; 5-8 December 2020, XP093065753, ISSN: 0006-4971, DOI: 10.1182/blood-2020-142695 *
DERIPPE T ET AL: "Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia", CANCER RESEARCH COMMUNICATIONS, vol. 2, no. 11, 30 November 2022 (2022-11-30), pages 1532 - 1544, XP093066171, ISSN: 2767-9764, DOI: 10.1158/2767-9764.CRC-22-0176 *
DOHNER ET AL., BLOOD, vol. 129, 2017, pages 424 - 447
DUPOUY S ET AL: "Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia", CANCER RESEARCH COMMUNICATIONS, vol. 2, no. 11, 30 November 2022 (2022-11-30), pages 1520 - 1531, XP093066170, ISSN: 2767-9764, DOI: 10.1158/2767-9764.CRC-22-0175 *
FREDERICK M. AUSUBEL: "Molecular Biology", 2000, OXFORD UNIVERSITY PRESS
GATTINONI ET AL., J. EXP. MED., vol. 202, no. 7, 2005, pages 907 - 912
GEORGE-GAY ET AL., J PERIANESTH NURS, vol. 18, no. 2, 2003, pages 96 - 114
HARRIS ET AL., J. AM. SOC. BLOOD MARROW TRANSPLANT., vol. 22, 2016, pages 4 - 10
HESS ET AL., MOL CELL, vol. 68, no. 1, 2017, pages 26 - 43
HOMBACH ET AL., CURR GENE THER., vol. 2, no. 2, 2002, pages 211 - 26
JENA, DOTTI ET AL., BLOOD, vol. 116, no. 7, 2010, pages 1035 - 44
JEONG ET AL., NAT BIOTECHNOL, vol. 39, 2021, pages 1426 - 1433
KOMOR ET AL., NATURE, vol. 533, no. 7603, 2019, pages 420 - 424
LEE ET AL., BIOL BLOOD MARROW TRANSPLANT, vol. 25, 2019, pages 625 - 638
LEE ET AL., SCIENCE ADVANCES, vol. 6, no. 29, 2020
LICKEFETT B ET AL: "Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle", FRONTIERS IN IMMUNOLOGY, vol. 14, 22 December 2023 (2023-12-22), XP093127762, ISSN: 1664-3224, DOI: 10.3389/fimmu.2023.1303935 *
LIU ET AL., CELL RES, vol. 27, 2017, pages 154 - 157
MAEDER ET AL., MOLECULAR THERAPY, vol. 24, no. 3, 2016, pages 430 - 446
MOK ET AL., NATURE, vol. 583, 2020, pages 631 - 637
MOLOSTOVA O ET AL: "CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALL", BLOOD, vol. 138, no. Suppl. 1, 5 November 2021 (2021-11-05), 63rd Annual Meeting of the American-Society of Hematology; Atlanta, GA, USA; 11-14 December 2021, pages 1737 - 1738, XP093065893, ISSN: 0006-4971, DOI: 10.1182/blood-2021-153414 *
MURANSKI ET AL., NAT. CLIN. PRACT. ONCOL., vol. 3, no. 12, 2006, pages 668 - 681
NINOMIYA ET AL., BLOOD, vol. 125, no. 25, 2015, pages 3905 - 3916
NUCLEIC ACID HYBRIDIZATION, 1984
OLIVER-CALDES A ET AL: "First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. 12, E003783, 7 December 2021 (2021-12-07), XP093040224, DOI: 10.1136/jitc-2021-003783 *
PINGOUDSILVA, NAT. BIOTECHNOL., vol. 25, no. 7, 2007, pages 743 - 4
R. I. FRESHNEY: "Immunochemical Methods In Cell And Molecular Biology", 1987, COLD SPRING HARBOR LABORATORY
REES ET AL., NAT. REV. GENET., vol. 19, 2018, pages 770 - 788
ROBERT A. MEYERS: "Molecular Biology and Biotechnology: a Comprehensive Desk Reference", 1995, WILEY, JOHN & SONS, INC.
SACHDEVA ET AL., J. BIOL. CHEM., vol. 294, no. 14, 2019, pages 5430 - 5437
SALLMANN D A ET AL: "AMELI-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)", MOLECULAR THERAPY, vol. 31, no. 4, Suppl. 1, 1 May 2023 (2023-05-01), 26th Annual Meeting of the American Society of Gene & Cell Therapy; 16-20 May 2023, pages 51, XP093128095, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2023.04.017 *
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR
SCHWARTZ ET AL., J. CLIN. APHER., vol. 28, no. 3, 2013, pages 145 - 284
STAERK ET AL., CELL STEM CELL, vol. 7, no. 1, 2010, pages 15 - 9
VASU S ET AL: "A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)", BLOOD, vol. 140, no. Suppl. 1, 15 November 2022 (2022-11-15), 64th Annual Meeting of the American Society of Hematology; New Orleans, LA, USA; 10-13 December 2022, pages 7474 - 7475, XP093065887, ISSN: 0006-4971, DOI: 10.1182/blood-2022-167340 *
WALSER ET AL., VIRUSES, vol. 14, 2022, pages 2242
YAMANAKA ET AL., SCIENCE, vol. 322, no. 5903, 2008, pages 949 - 53

Similar Documents

Publication Publication Date Title
JP7410856B2 (ja) ドナー改変細胞の選択のための調節可能スイッチ
AU2017362484A1 (en) TGFβ signal convertor
GB2604416A (en) Tumor infiltating lymphocytes and methods of therapy
JP2019047801A (ja) Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
KR20200075000A (ko) 면역요법을 위한 t 세포 내 tgfbr2의 crispr-cas9 편집 방법, 조성물 및 성분
JP2016538861A (ja) 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法
WO2019002633A1 (fr) Immunothérapie cellulaire pour une administration répétitive
US10894093B2 (en) Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US20210268028A1 (en) Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
JP2024514203A (ja) Ｃｄ５陽性がんを標的とするキメラ抗原受容体
US20230060351A1 (en) A method of engineering natural killer cells to target cd70-positive tumors
US20230040477A1 (en) T-cell death associated gene 8 (tdag8) modulation to enhance cellular cancer therapies
US20190328783A1 (en) A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
WO2024121385A1 (fr) Régime à deux doses en immunothérapie
US20240342280A1 (en) Optimizing t cell differentiation state with micrornas
Marin et al. “Off the Shelf” CAR‐T/NK Cells
JP2024536279A (ja) 抗体を担持した免疫細胞及び癌治療における使用方法
AU2022267804A1 (en) New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
WO2023205705A2 (fr) Lymphocytes t allogéniques pour le traitement de malignités hématologiques
AU2022277649A1 (en) Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
WO2024062138A1 (fr) Cellules immunitaires comprenant un gène suv39h1 modifié
JP2020018323A (ja) 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23820929

Country of ref document: EP

Kind code of ref document: A1